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ABSTRACT 
Toxoplasma gondii is the most successful zoonotic pathogen known today.  One-third of people 
are chronically infected worldwide. Different strains of T. gondii shows variability in mouse 
virulence which may potentially correlate with disease manifestation in humans. As a result, 
mouse is used as the model organism to study the virulence of T. gondii strains. To study the 
virulence on a global scale, it is necessary to establish a standardized approach for mice 
virulence assays. Thus, we review the methodologies used in different labs and put forth 
standardized approaches to study the T. gondii virulence in mice (Chapter 1). Recent 
advances in diversity and population structure of T. gondii had shown that even though the 
dominant type II strain is spread globally, it is particularly dominant in the region of Europe. 
Thus, to understand the origin and transmission pattern of the type II dominant lineage of T. 
gondii (Chapter 2), we tested the hypothesis that the current distribution structure and 
dominance of type II T. gondii in Europe is because the most recent common ancestor 
(MRCA) of type II originates in the continent of Europe. Based on our study we found that 
type II dominant lineage originated in the Old World and has transmitted to the New World 
(America). To further examine the migration pattern of second most dominant type III T. gondii, 
diversity among isolates was analyzed.  Based on previous knowledge, in Chapter 3 we tested 
the hypothesis that, despite the diversity of genotypes in South America, the higher 
frequency of type III lineage is because the most recent common ancestor (MRCA) of type 
III originated on this continent. Our study revealed that origin of type III lineage is in the New 
World close to Central America and that the dissemination pattern is from New World to the Old 
World. In Chapter 4 we studied the seroprevalence rates for 471 and genotyped (n=19) wild life 
samples of T. gondii in the southeastern United States. We found high seroprevalence rates 
amongst game meat animals (white-tailed deer and feral hogs) which could be a potential 
risk for humans consuming contaminated meat. 
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1. Overview 
Toxoplasma gondii is one of the most successful pathogens on earth, capable of infecting a broad 
range of mammals and birds [1]. It belongs to the phylum apicomplexan which also includes 
other medically significant members such as Plasmodium, Cryptosporidium, and Babesia. Felids 
are the only known definitive hosts in which sexual replication of the parasite occurs, resulting in 
the dissemination of oocysts into the environment via defecation, thus felids play a critical role in 
the transmission of T. gondii. Mammals and birds are intermediate hosts in which asexual 
replication of T. gondii occurs, which generates a large number of fast-replicating tachyzoites 
during acute phase infection. This phase is followed by a growth switch to slow-growing 
bradyzoites in tissue cysts. It is estimated that one-third of the world’s human population is 
chronically infected with this parasite [1]. Humans become infected by ingesting oocysts from 
contaminated food and water, consuming undercooked meat containing the tissue cysts, or 
vertical transmission of tachyzoites from mother to fetus [1, 2]. Primary infection in 
immunocompetent individuals is mostly asymptomatic but in some cases can lead to ocular 
toxoplasmosis [3]. In immunocompromised individuals, such as AIDS patients, reactivation of 
chronic infection can cause life-threatening encephalitis [1, 4].  
 
2. Life Cycle  
Toxoplasma gondii has three distinct forms: 1) sexually-reproduced sporozoites, 2) the fast-
replicating tachyzoites, and 3) slow-replicating bradyzoites. Sexual replication of T. gondii is 
restricted to felids. Felids can ingest oocysts from environmental sources or tissue cysts from 
chronically infected prey [1, 2] (Figure 1.1). The cyst wall is ruptured due to acid pepsins 
present in the felids stomach. Once released, the sporozoites or bradyzoites invade the epithelial 
cells of the intestine and differentiate into schizonts. The parasite then forms merozoites which 
later differentiate into male and female gametes. The gametes fuse together to form diploid 
oocysts and are shed in the feces of the felines.  The time between the infection and shedding of 
oocysts is generally 3-10 days [1, 5]. A single cat can shed up to 20 million oocysts per day in its 
feces [6]. When released in the environment, these oocysts can sporulate under ambient 
temperatures producing eight haploid sporozoites enclosed in the wall of the cyst. The oocysts 
can survive in moist soil and water for up to 18 months which prolongs their survival in the harsh 
environments [7].  
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          Almost all warm-blooded animals and birds can serve as an intermediate hosts for T. 
gondii. Intermediate hosts are infected via sporozoites in oocysts from contaminated water 
sources as well as via tissue cysts in contaminated meat sources (Figure 1.1). On ingestion of 
oocysts, the sporozoites are detectable in the small intestine within hours of infection [8]. The 
sporozoites then differentiate into tachyzoites and replicate rapidly [1]. Upon consumption of 
contaminated meat containing tissue cysts, the cyst wall is dissolved due to acid-pepsin in the 
host’s stomach and bradyzoites are released. In mice, bradyzoites differentiate into tachyzoites 
within one hour and enter into a rapidly- replicating form by two hours post infection. Fast 
replicating tachyzoites enter the lymph nodes by 48 hours and can disseminate by infecting 
migratory cells like dendritic cells and macrophages[1]. Eventually, the tachyzoite form is 
converted to a more slowly-replicating, dormant form of bradyzoites. Bradyzoites enclosed in the 
cyst wall are resistant to immune responses and are retained primarily in brain and muscle for the 
lifespan of the infected host [8, 9].  
 
3. Virulence 
Susceptibility differences to T. gondii infection have been reported among closely related species 
[1]. For examples, rats (genus Rattus) are generally resistant (form chronic infection) to 
toxoplasmosis, whereas house mice (Mus musculus) are highly susceptible compared to most 
other hosts[1]. Mice are generally selected as the model organism for testing the virulence of 
Toxoplasma. As house mice are more susceptible to T. gondii, a difference in the susceptibility is 
observed among different strains of the parasite. Toxoplasma strains can, therefore, be classified 
into virulent and avirulent categories. Parasite strains causing 100% mortality in mice at a dosage 
of as low as one parasite are considered to be virulent. Some strains, on the other hand, require a 
high dosage to achieve mortality, and subsequent infection with low dosage leads to chronic 
infection in mice [10, 11]. In the early 1990’s using PCR-RFLP (Polymerized chain reaction- 
Restriction fragment length polymorphism) based genotyping of strains it was observed that all 
the virulent strains fall in the 
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Figure 1.1: Life cycle of T. gondii [222]. 
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category of type I lineage and non-virulent strains belonged to either the type II or III lineages of 
the parasite [10, 12]. Later, PCR-RFLP based genotyping study on T. gondii samples from  
Europe and North America suggested that the population structure of Toxoplasma was 
dominated by the three clonal lineages type I, II and III [11]. This observation led to the 
investigation of the genetic differences among the lineages and how they lead to differences in 
mouse virulence.  
 
4. Genetic Basis for Differences in Virulence  
The first evidence for virulence differences emerged from mapping the progeny from sexually 
crossed type I, II and III clonal lineages using Quantitative Trait locus (QTL) analysis [13] [14]. 
From these studies, two major virulence genes rhoptry protein 18 (ROP18) and ROP5 were 
identified in T. gondii [13-15].  The first key virulence factor identified was the ROP18 kinase 
[14].  The main function of ROP18 is to interact with immunity-related GTPases (IRGs) and p65 
guanylate binding proteins (GBPs) that are known to localize to the parasitophorous vacuole 
membrane (PVM), ultimately causing disruption of the PVM and leaving the parasites 
vulnerable to clearance by other host defense mechanisms [16-19]. Thus, functional ROP18 is 
required by T. gondii for evasion of the host immune system.  In the crosses generated, it was 
revealed that types I and II express a functional ROP18 allele and are thus included in the 
virulent category. In contrast, the ROP18 allele of type III clonal lineage has an insertion in the 
promoter region that attenuates expression of the gene, making it non-functional [20]. ROP5 is a 
rhoptry-secreted pseudo kinase, non-functional kinase by itself due to a mutation in the catalytic 
site and is correlated even more strongly with virulence than ROP18 [21]. ROP5 plays a role in 
the suppression of the immune system via formation of a complex with ROP18 and murine IRGs 
[21, 22]. Functional ROP5 alleles are expressed by clonal types I and III. In the case of type I 
strains, the expression of both functional ROP5 and ROP18 alleles appears to account for the 
hyper virulence of this lineage. On the other hand, the ROP5 allele of type II is nonfunctional, so 
that this strain type is avirulent despite expression of functional ROP18 [15, 22]. ROP17 is 
another rhoptry protein that was found to interact with ROP5. The combination of ROP17 and 
ROP5 also determines virulence similar to RO18 and ROP5 interaction but the interaction is less 
significant in comparison to the combination of ROP5 and ROP18 [21]. Recently, using PCR –
RFLP technique, genotyping was performed for four loci ROP5, ROP18, ROP 16 and ROP17 for 
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240 strains collected globally [23]. Comparing the genotyping data with the previously published 
mouse virulence data for these strains, it was shown that there is indeed an association between 
the genotypes of the ROP5 and ROP18 allele and virulence in mice. ‘ 
 
5. Human Toxoplasmosis 
One-third of the human population is infected with T. gondii [24]. For immunocompetent 
individuals, the general symptoms of the acute infection include fatigue, fever, muscle and joint 
pain [1]. Approximately two weeks after acute infection, the parasites enter into the chronic 
phase and maintain infection for the entire life of infected host [25, 26]. In the United States, the 
seroprevalence rate ranges between 10-38%. In other regions like China, UK and Korea the 
seroprevalence percentage is lower and estimated to be 11, 8 and 4% respectively [1, 3]. These 
geographical differences in the infection rate are the reflection of the dietary habits in that 
particular region. However, severe cases of toxoplasmosis are typically reported in 
immunocompromised people like AIDS, cancer or organ transplant patients. The majority of 
AIDS patients infected with Toxoplasma suffer from formation of necrotic lesions in the brain, 
which are associated with encephalitis as well as pneumonia and other systemic forms of the 
disease. These severe cases of toxoplasmosis are a result of reactivation of latent infection when 
the immune system is compromised or suppressed [1]. However, recent studies have also 
reported severe cases of toxoplasmosis in immunocompetent people [3, 27-29]. 
 
5.1 Ocular Toxoplasmosis   
Ocular toxoplasmosis (OT) is one of the most common infections observed in nearly 18% of 
adults in Southern Brazil compared to 2% of adults in Europe and the United States [3].  The 
infection can result in scarring of the ocular tissue leading to vision impairment. A large number 
of ocular toxoplasmosis cases in South America manifest more severe clinical symptoms. For 
example, eye lesion and impaired vision cases are more common in children and the lesions 
formed are much larger in size and multi focal when compared to cases from Europe. This 
relatively high number and increased severity in South America is hypothesized to be linked to 
the atypical strains of T. gondii dominant in regions like Brazil.  Similarly, another study in 2011 
reported that 18 out of 20 tissue samples collected from toxoplasmosis patients in Sao Paulo, 
Brazil belonged to genotype # 65 which comprises a small fraction of total T. gondii strains 
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found in this region [30]. Additionally, the majority of Colombian OT patients were found to be 
infected with atypical or type I virulent strains of T. gondii [30]. All this evidence indicates that 
the strains circulating in the environment determine the disease manifestation in humans residing 
in that region.  
 
5.2 Congenital Toxoplasmosis 
Toxoplasma can also be vertically transmitted from mother to fetus and, as a result, is a major 
health concern for pregnant women. The higher seroprevalence rates reported in pregnant 
women also highlights this threat. Seroprevalence rates as high as 61% and 84% were 
documented in France and Madagascar respectively. In regions like Brazil where undercooked 
meat is consumed daily, the seroprevalence can range between 61-92% [3, 31]. In general, 
pregnant women infected for the first time during pregnancy can vertically transmit the parasite 
to the developing fetus during the acute infection stage. Even so, few cases of vertical 
transmission have been reported due to chronic infection or preexisting infection before 
pregnancy [32]. Thus, women infected during pregnancy are likely at a greater risk for 
abnormalities in the fetus.  The severity of the symptoms due to the vertical transmission varies 
depending on the gestational stage of the pregnancy.  More severe outcomes of infection are 
reported during the first trimester of pregnancy, while infections occurring during the later stages 
of pregnancy have less severe symptoms, but are more prone to congenital infection. The 
manifestation of the infection during pregnancy can include ocular disease, congenital defects 
and pregnancy loss [1]. 
 
5.3 Severe Disseminated Toxoplasmosis 
Severe cases of toxoplasmosis have also been reported in the population of French Guiana [28]. 
Of the 44 cases of severe primary toxoplasmosis reported from the period of 1998-2004, one- 
third were hospitalized for respiratory distress. Genotyping studies revealed that the majority of 
strains infecting these patients belonged to the atypical category. In addition, 11 cases of multi-
visceral toxoplasmosis were reported from Patam village in French Guiana from December 2003 
to January 2004. Eight out of 11 patients were found to be immunocompetent and genotyping 
studies revealed one atypical genotype infecting all the patients [28]. Organ failure was also 
reported in 11 immunocompetent adults of French Guiana, thus requiring intensive care. This 
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severe form of systemic toxoplasmosis called ‘Amazonian toxoplasmosis’ and is speculated to be 
a result of spillage of strains circulating among wild animals to intermediate hosts like humans 
and domestic animals in that region [28, 33]. Wild definitive hosts are generally more resistant to 
T. gondii which leads to the selection of more virulent strains causing more severe infection in 
the intermediate hosts in close proximity. In other regions like Europe, where type II strains are 
found to be most dominant, the majority of OT cases were found to be caused by the virulent 
type I or atypical strains of T. gondii [34, 35].   
 
6. Population Structure 
Early genotyping studies of 106 isolates from Europe and North America using 6 PCR-RFLP 
markers divided T. gondii isolates into three clonal types denoted as types I, II and III [11]. It 
was suggested that the global population structure of T. gondii was largely clonal with three 
archetypical lineages (type I, II and III) dominating the entire world. However, recent advances 
have revealed that the population structure of T. gondii is more complex than previously thought 
[36, 223]. The most recent data on diversity structure of Toxoplasma have been obtained from a 
study performed on 1457 isolates using 10 PCR-RFLP markers (Figure 1.2) [36]. A total of 189 
ToxoDB PCR-RFLP genotypes were found from these isolates of T. gondii collected worldwide. 
The population structure in the northern hemisphere appears to be largely clonal, whereas the 
southern hemisphere samples show a diverse population structure. In Europe, the majority of the 
isolates studied belonged to ToxoDB genotypes #1 and #3 that together are recognized as type II 
lineage [223]. The second dominant lineage in Europe was found to be #2 that is known as type 
III lineage. However, genotype #10 (type I) [223] constituted a relatively lower percentage of the 
total population. This shows that the European population structure is mostly clonal which is in 
agreement with previous report [11]. In North America, the majority of the population is 
comprised of genotype #1 or #3 (type II) [223]  strains, whereas genotype #2 (type III) strains 
were also found in relatively higher frequency. Interestingly, genotypes # 4 and # 5, together 
known as type 12 [223] were found in high frequency in wildlife. In Eastern Asia, genotype #9 
(Chinese type I) was found to be widespread followed by #10 [223]. Other genotypes identified 
in this region were genotypes #4, #18 and #20 [223]. Overall, the population structure in Asia 
was recognized to be clonal. In Africa, #2 and #3 accounted for the majority of the isolates. 
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 Figure 1.2:  Population structure and diversity of T. gondii on a global scale [36]. 
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Additionally, genotype #6 was observed [223]. Unlike other regions, the population structure in 
Central and South America is highly diverse and there is a lack of predominant lineages. 
Commonly found genotypes included in decreasing order, #2, #6, #7, #8, #11, #3, #65, #13, #19 
and #146. However, in the geographical region which includes Chile, the three lineages 
including ToxoDB genotype #1, #2 and #3 were found to be predominant (Figure 1.2) [36]. 
Overall, the current population structure for Toxoplasma appears to be much more complex with 
the northern hemisphere showing a clonal structure, compared to the southern hemisphere which 
is more diverse.  
 
7. Immune Responses 
 
7.1 Interferon Gamma  
Interferon gamma (IFNγ) is one of the most important Th1 cell-mediated cytokines critical for 
the control of T. gondii infection. Mice lacking the IFNγ gene have been shown to succumb to T. 
gondii infection. The major cells producing IFNγ include neutrophils, T cells and NK cells [37-
39]. The main function of IFNγ is the expression of immunity related GTPases (IRGs) and 
guanylate binding proteins (GBPs) [40-42]. The role of IRGs and GBPs is to disrupt the integrity 
of the PV membrane leading to the release of the parasites in the host cytoplasm [43]. IRG 
proteins can be divided into two groups (GKS and GMS) depending on their specific role. 
Effector proteins (GKS) bind to the parasite membrane and are responsible for mechanically 
disrupting the membrane. On the other hand, regulatory proteins (GMS) are required for 
protection of the host intracellular membrane to prevent disruption via GKS proteins [18, 44]. 
The role of GBPs in parasite clearance is rather indirect and requires the recruitment of other 
IRG proteins [42]. In addition to the expression of IRGs and GBPs, IFNγ also aids in limiting the 
replication of the parasite by inhibiting tryptophan production. Interferon gamma induces the 
production of indoleamine 2, 3- dioxygenase that converts tryptophan into an unusable form. As 
T. gondii is a tryptophan auxotroph, the absence of tryptophan limits the parasite growth [45, 
46].  IFNγ can also play a role in parasite inhibition via production of reactive oxygen and 
nitrogen species (ROS and RNS) that have antimicrobial properties. It does so by inducing the 
NO synthase gene using L-arginine as the substrate [47, 48].  
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7.2 Tumor Necrosis Factor Alpha  
Tumor necrosis factor Alpha (TNFα) alone cannot trigger parasite clearance and requires the 
help of IFNγ [49]. Activated macrophages when primed with IFNγ and TNFα show enhanced 
antimicrobial activity [50]. TNFα in conjunction with IFNγ can lead to parasite control by fusion 
of PV to the lysosomes causing their degradation [51]. In macrophages, TNFα also plays a role 
in the production of RNS having antimicrobial activity [52, 53]. TNFα can also act as a co-
stimulatory molecule in NK cells. It has been shown that NK cells exposed to parasite antigen 
along with TNFα produce IFNγ [37].  
 
7.3 Interleukin -12 (IL-12) 
Th1 cell-mediated response is known to be critical for parasite clearance; this is in part mediated 
by upregulation of IL-12 which is required for the production of IFNγ [39, 54].  Mice infected 
with lethal doses of the parasite shows enhanced survival on treatment with exogenous IL-12 
[55]. The major circulatory cells involved in the IL-12 production are dendritic cells, monocytes 
and neutrophils [56, 57]. In response to the secretion of chemokines like macrophage 
inflammatory proteins 1 and 2 on infection with T. gondii, macrophages and neutrophils are 
recruited to the lumen of the small intestine in mice [58-60]. This leads to the clearance of 
parasites via processes like phagocytosis, antigen presentation and involvement of other immune 
cells [57, 61-65]. The production of IL-12 is dependent on myeloid differentiation factor 88, 
which is recruited to TLRs on the binding of pathogen-specific molecules [66]. 
  
7.4 Adaptive Immune Response 
T and B cell mediated response is critical for the survival of humans as well as mice, especially 
during the chronic infection stage. CD4+T cells are involved in the production of IFNγ as well as 
mediation of B and CD8+T cell responses. CD8+ T cells, in turn, offer protection via production 
of IFNγ and CD40L as well as perforin-mediated lysis of infected cells [67, 68]. CD4+T cells are 
activated by dendritic cells (DCs) which are one of the most important antigen presenting cells 
(APCs), in addition to other cells like B cells and macrophages [69]. B cell activation, in turn, 
produces antibodies that provide protection via activation of complement pathway and 
opsonization of the pathogen. CD8+ T cells are activated by T. gondii antigens like surface 
antigen 1 (SAG1), dense granule proteins (GRA4 and GRA6) and rhoptry protein ROP7 [70].  
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8. Interconversion and Disease Pathogenesis 
The life cycle of Toxoplasma consists of three stages sporozoites, tachyzoites, and bradyzoites. 
Infections in immunocompetent individuals are mostly asymptomatic [1]. However, the key to 
disease pathogenesis of this parasite is in part linked to its ability to convert into a dormant, 
slowly replicating bradyzoite enclosed within a tissue cyst. Tissue cysts can hide from the 
immune system and remain in the host indefinitely [71]. However, in immunocompromised 
people such as AIDS patients or chemotherapy patients, tissue cysts can rupture and release 
bradyzoites. Transformation of bradyzoites into tachyzoites can lead to parasite reactivation and 
in some cases severe disseminated toxoplasmosis and life-threatening encephalitis. Therefore, 
understanding the mechanisms behind the ability of tachyzoites to convert to bradyzoites is of 
utmost importance. The combination of drugs like sulfonamide and pyrimethamine are 
commonly used to control the active infection. Sulfonamide is known to interfere with the folic 
acid biosynthesis pathway by preventing the addition of para-amino benzoic acid (PABA). 
Pyrimethamine, on the other hand, is a dihydrofolate reductase that blocks the biosynthesis of 
purine and pyrimidines. Although drugs which control the tachyzoites in the active stage of 
infection currently exist, no successful drugs have been developed to control the chronic 
infection bradyzoite form [1, 72]. Hence, knowledge of the molecular prerequisites for 
interconversion can be used to force the parasite into tachyzoites stage and then be targeted by 
using known drugs. 
 
8.1 Bradyzoites 
Toxoplasma in the form of cysts can be maintained indefinitely in almost all the intermediate 
hosts thereby sustaining its infectivity [8]. Within 2 hours of ingestion of oocysts, sporozoites are 
detectable in the epithelial cells of the small intestine [1]. By 12 hours post infection, sporozoites 
differentiate into tachyzoites and enter into a rapidly replicating stage by 48 hours [1, 73]. The 
other route of infection in intermediate hosts is the ingestion of cysts in the contaminated meat. 
Once tissue cysts are ingested by intermediate hosts, the cyst wall is digested by acids present in 
the stomach. In mice, tachyzoites are detectable in epithelial cells 2 hours after infection. When 
migratory cells like dendritic and macrophages are infected, tachyzoites spread in the host [74]. 
Eventually, factors like immune pressure or spontaneous conversion lead to conversion of 
tachyzoites to the dormant bradyzoite form enclosed within the cyst wall [8]. Tissue cysts are 
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formed within 6 to 7 days post infection. Cysts can be harbored for decades primarily in the 
brain, skeletal muscle, and cardiac tissues. The reason why cysts are predominantly found in 
these cells is not well understood. Bradyzoites are generally believed to be dormant however, 
they can rupture periodically during the life time of an individual for reasons not yet known, 
leading to reactivation of the disease [1].  
 
8.2 Bradyzoites and Human Health 
It was 50 years after the discovery of Toxoplasma when it was recognized that the parasite can 
disseminate via contaminated meat sources [75]. This highlighted the fact that consumption of 
undercooked meat may prove as one of the major routes of infection in humans and other 
intermediate hosts. Upon ingestion of the tissue cysts via contaminated meat, bradyzoites are 
released in the intestinal epithelial cells of the intermediate host and the asexual life cycle begins. 
Later in the life cycle, the parasites enter into a slowly replicating dormant stage of bradyzoites 
enclosed in tissue cysts[1]. Once an infection is established the parasite can maintain its 
infectivity as tissue cysts, for the entire life span of the host. Even though bradyzoites are 
believed to be dormant, in the conditions of immune suppressed conditions, e.g. cancer and 
AIDS, the parasite can emerge from latency and convert back to the tachyzoites form and 
reinvade other nucleated cells [76]. Thus, in 1980 when AIDS emerged, Toxoplasma became a 
major threat [77]. Since bradyzoites can reside in different organs in humans, it is an additional 
cause of concern during organ transplant procedures. These findings led to the beginning of 
intense research for the understanding of important regulatory factors for switch between the 
acute and chronic infection stages.  
 
8.3 Surface Proteins and Heat Shock Proteins 
Stage conversion from tachyzoite to bradyzoite is associated with changes in the stage-specific 
surface antigens (SAG) [78]. The SAG superfamily of antigens can be divided into SAG1 and 
SAG2 family of surface antigens [79]. The SAG1 family of proteins plays a role in surface 
attachment of the parasite before the invasion.  The SAG1 family comprises of SAG3, bradyzoite 
specific recombinant BSR4, SAG related sequences (SRS) 1-4 proteins, SAG 5, SAG5.1 and 
SAG5.2 [79]. SRS1-3 is specific to the tachyzoite stage, BSR4 is specific to bradyzoites and 
SAG3 is found in both stages. Similarly, the SAG2 family consists of SAG2A and SAG2B-D. 
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SAG2A and SAG2B are antigens specific to tachyzoite stage. On the other hand, SAG2C and D 
are specifically expressed in the bradyzoite stage [80]. These differentially expressed surface 
proteins can be used as a marker for the identification of parasite stages in in vitro assays. 
Heat shock proteins (HSPs) are another family of stress-related proteins required for bradyzoite 
development. Experiments using the drug Quercetin which specifically inhibit HSPs have shown 
the suppression of the stage conversion process. Bradyzoite specific-antigen (BAG1), previously 
known as HSP30, is a bradyzoite stage specific HSP commonly used to identify the cyst form in 
cell culture experiments [81]. Studies have shown that deletion of the BAG1 gene reduces the 
number of cysts in in vitro assays [82]. 
 
8.4 Triggers and Determinants of Bradyzoite Formation 
 
In vivo determinants of tachyzoites to bradyzoite conversion  
Various in vivo factors such as parasite cell cycle, stage specific metabolites, host cell type, 
manipulation of host immune responses, translation and transcription regulation, cyclic 
nucleotides, etc. are known to play a role in the differentiation process of T. gondii. These factors 
are discussed below in more detail. 
        Bradyzoite development and maintenance is dependent on transcription of the required 
genes which in turn is tightly regulated with the cell cycle stage of the parasite. Abrupt cessation 
of the cell cycle does not lead to bradyzoite development of the parasite, which suggests that the 
parasite requires the completion of the cycle in order to enter the G0 phase for completion of 
differentiation process [83]. Mature bradyzoites isolated from the brains of mice infected with 
oocysts were found to be stalled in the G0 phase of the cell cycle containing 1N DNA. On the 
other hand, differentiating parasite population contained 1.8 to 2 N DNA and was discovered to 
be in the S/G2 phase of the cell cycle [84, 85]. This shows that commitment to bradyzoite 
formation requires an entry into the pre-mitotic phase.  
        The metabolism profile of the parasite is linked to the stage of life cycle. Metabolomics 
studies have identified stage-specific isoforms of enolases (ENO 1 and 2) and lactate 
dehydrogenases (LDH 1 and 2) [86, 87]. The LDH2 form of the enzyme LDH is found to be 
specific to the bradyzoite stage and is resistant to acidic pH, making it functional during the 
catabolism of amylopectin in bradyzoites [87]. This is in accordance with electron microscopy 
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studies that show an increase in the number of amylopectins during the bradyzoite stage [88]. 
The enzyme enolase also shows stage dependent differences in the specificity and stability in the 
interconversion phenomenon. This enzyme catalyzes the conversion of 2-phosphoglycerate (2-
PG) to phosphoenolpyruvate (PEP) in glycolysis [86]. The specificity of the bradyzoite stage- 
specific ENO1 form is three-fold greater than ENO2, even though both the isoforms have the 
same Michalis constant (km). This indicates that stage-specific glycolytic flux can be regulated 
via expression of different isoforms of enzymes [86].  
        The role of host cell type in differentiation is still unclear. Given that cysts predominate in 
brain and muscle cells and that the yield of tachyzoites varies between different host cell types, 
identifies the need of the elucidation of this process. The host cell type differences could be 
attributed to several factors. It is possible that as neuron cells in the brain and muscles are long-
lived, the chances of finding cysts in these cells for a longer period of time is increased [9]. In 
addition, the slowing of parasites replication, directed by host cell microenvironment, could also 
promote the differentiation. Studies using Compound 1(4-[2(4-flurophenyl)-5-(1-methyl 
piperidine-4-yl)-1 H pyrrol-3-yl] pyridine), support this hypothesis [89, 90]. It was observed that 
only Hela cells treated with compound 1 increase the expression of the human cell division auto 
antigen 1(CDA1), which slows the parasite replication, thereby increasing the number of cysts 
[91]. Parasites also exhibit spontaneous differentiation in certain cell types such as rat-isolated 
CNS cells including microglia, neurons, and astrocytes, primary and continuous muscle cells for 
type III VEG strain of T. gondii [92, 93]. This further supports the possible role of the host cells 
in the differentiation process.  
        T. gondii has been shown to develop multiple strategies to evade the host immune 
responses, as well as manipulate the cytokines required by hosts for its own benefit. It is known 
that IFNγ dependent cell- mediated immunity is critical for killing the parasites during the acute 
infection phase [41, 42]. Additionally, prolonged IFNγ treatment is required to kill the rapidly 
dividing reactivated tachyzoites. However, in vivo experiments using mice infected in the 
presence of IFNγ have shown that IFNγ promotes differentiation into bradyzoites [94]. It is 
speculated that this effect is due to the induction of the nitric oxide synthase gene to form nitric 
oxide [95, 96]. Treatment of cells with NO donor (sodium nitroprusside) causes an increase in 
the number of cysts formed in vitro [81, 82, 92]. IL-12 is another key cytokine required for 
protection of the host. Mice lacking IL12 succumb to the parasite infection due to uncontrolled 
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replication [39, 55]. IL-12 is produced on the translocation of NF-kB from the cytoplasm to the 
nucleus when pathogen -specific molecules bind to toll-like receptors (TLRs) and MyD88 is 
recruited to the TLRs. Type I and III strains of Toxoplasma have been shown to block the NF-kB 
translocation, thereby hindering IL-12 production [97-99]. In contrast, type II strains of T. gondii 
promote the expression and translocation of NF-kB via secretion of GRA15, thereby increasing 
the proinflammatory response [100]. Type II strains adapted to the proinflammatory response 
increase in the host to maintain chronic infections for a longer period of time. Toxoplasma also 
avoids killing by suppressing the production of NO, especially in macrophages. NO is produced 
by nitric oxide synthase using arginine as the substrate. Toxoplasma secretes rhoptry protein 
ROP16 that activates the STAT6 pathway in the host leading to the expression of arginase 1. 
Arginase 1 is known to degrade arginine, thereby reducing NO production [47, 101]. As NO has 
an antimicrobial property, limited NO availability proves beneficial for the parasite. 
Furthermore, Toxoplasma being an arginine auxotroph requires exogenous arginine, and so, 
limited NO availability decreases the rate of parasite replication, which then helps in the 
differentiation process [101]. NO production is also blocked by a patatin like phospholipase 
(TgPL1) [102, 103]. Lower levels of cytokines were found at 8 weeks post infection in mice 
vulnerable to toxoplasmic encephalitis (TE) [104]. On the other hand, mice infected with a 
mutated strain lacking the TgPL1 gene maintained high cytokine levels, protecting them from TE 
symptoms. Thus TgPL1 is required for suppression of NO, leading to lower cytokine levels, and 
formation of cysts in the brain [104]. 
        Translation regulation can also play a role in regulating the differentiation process. 
Eukaryotic initiation factor-2 (eIF2) is one of the most characterized factors known to play a role 
under different stress conditions [105]. Similarly, in T. gondii, protein translation is blocked 
when the alpha subunit of TgIF2α is phosphorylated by protein kinases TgIF2K-A to D [106, 
107]. This reduced protein translation helps Toxoplasma to stall the parasite at the tachyzoite 
stage in order to promote the induction of bradyzoite stage genes.  
        Transcriptome analysis of T. gondii at different stages of the life cycle revealed that stage 
differentiation in T. gondii is a transcriptionally governed process. Recent studies have identified 
a role of the plant AP2-like domain containing T. gondii protein (TgAP2XI-4) in acting as a 
transcriptional regulator to control the expression of bradyzoite stage-specific genes [108]. This 
AP2 domain containing protein localizes in the nucleus, and binds to the ‘CACACAC’ sequence 
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specific DNA motif, and its expression peaks after cytokinesis [109]. Transcript levels of this 
protein were higher in cysts isolated from the brain than in rapidly dividing tachyzoites. Thus, 
transcription regulation of stage-specific genes can govern the parasite differentiation. 
The role of cyclic nucleotide pathways in differentiation was studied in two T. gondii strains 
ME49 and PLK. The numbers of bradyzoites were increased in vitro when HFF cells, infected 
with T. gondii strains, were treated with cGMP and cAMP nucleotides [110, 111]. Additionally, 
infection conducted using forskolin, an agent used to transiently increase cAMP levels, induced 
tachyzoite differentiation [110]. Further investigations revealed the involvement of the protein 
kinase catalytic subunit TgPKAc3 in the bidirectional regulation of differentiation [110]. This 
suggests that cyclic nucleotide signaling pathways are involved in stress- induced differentiation 
and are dependent on protein kinase subunit -3 [110].  
        Bradyzoite pseudo kinase 1 (BPK1) expressed during early stages of cyst formation, was 
found to be influential in the infectivity and development of cysts [112, 113]. Using 
immunoprecipitation techniques, BPK1 was found to interact with four associated proteins; 
MAG1, MCP4, GRA8 and 9. Deletion of the BPK1 gene resulted in the formation of cysts that 
were smaller in size with lower oral infectivity [113].  
        Some strains of T. gondii show spontaneous stage conversion in vitro. Sporozoites or 
bradyzoites of the VEG strain (ToxoDB genotype #2, type III) were inoculated in HFF cells and 
were found to readily convert into tachyzoites stage. After approximately 20 divisions, the 
sporozoites slowed their growth uniformly leading to bradyzoite formation [84, 85]. Specific T. 
gondii strains are therefore able to follow a defined course of development without the need for 
any external factors.  Serial analysis of gene expression profile (SAGE) also revealed that a 15-
day sporozoites culture contained a mixed population of tachyzoite and bradyzoite stage 
parasites, with a gene expression profile similar to pH stressed parasites [85]. Together, these 
data suggest that parasites are programmed to slow their replication in order to enter into the 
bradyzoite stage.  
 
In vitro Stresses Inducing Bradyzoite Formation 
Exogenous stress can trigger differentiation, leading to cysts formation in vitro. Immunological 
factors are therefore not necessary to trigger bradyzoite development. Discussed below are the 
   
 
18 
 
commonly used external stress inducers and stress related changes in the parasite which lead to 
the conversion of tachyzoite to bradyzoite.  
        Growing Toxoplasma under alkaline conditions is one of the most commonly used 
strategies for bradyzoite development [114-116]. Experiments using human fibroblast cells 
(HFF) infected with the ME49 strain of T. gondii were shown to readily form cysts (3-4 days) by 
using an alkaline pH medium [116]. Changing the pH of the medium after infection or 
preconditioning of the HFF cells in alkaline pH for an hour before invasion leads to bradyzoite 
formation [114]. Use of alkaline pH conditions, however, is not considered to be a 
physiologically relevant stress factor [114]. This is of concern when trying to identify the 
molecular mechanisms behind the conversion process. 
        Tachyzoites can be converted to bradyzoites in vitro using heat stress. Studies have 
identified a role of heat shock family proteins (HSPs) in the conversion of tachyzoites following 
heat stress [81, 114]. HSP30/Bag1, HSP72, and HSP90 are a few HSP family proteins that have 
been identified to play a role in cysts production [81, 117, 118]. When parasites are allowed to 
invade preconditioned thermotolerant human fibroblast cells (HFF) cells at 37°C and then are 
heat shocked for 2 hours at 43°C, they readily form cysts in vitro [119, 120]. It currently remains 
unknown whether fever/high- temperature conditions symptoms during acute toxoplasmosis in 
humans induces the bradyzoite formation. 
        Of all the methods currently used to study conversion of tachyzoites to bradyzoites, use of 
NO is most physiologically relevant [81, 95, 110]. In vivo, NO is produced in response to the 
production of IFNγ and acts on the iron-sulfur center of proteins involved in the parasite 
respiratory chain [95, 121]. Sodium nitroprusside (SNP) is the most commonly used NO donor 
drug in in vitro experiments and triggers bradyzoite differentiation in almost all host cell lines 
[81, 92, 95].  
        Tachyzoites replicate faster than bradyzoites and as a result, require a higher concentration 
of nutrients. Recent studies have shown that deprivation of the amino acid arginine induces the 
formation of bradyzoites [122]. Toxoplasma, an arginine auxotroph, relies on the host arginine 
supply [122]. Thus, in the absence of external arginine, replication of the parasite is blocked, 
leading to the formation of bradyzoites. Additionally, inhibition of pyrimidine de novo 
biosynthesis and the salvage pathway has also shown to induce conversion of tachyzoites. T. 
gondii has a truncated pyrimidine salvage pathway and thus requires uracil phosphoribosyl 
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transferase gene (UPRT), as well as CO2, for the de novo synthesis of pyrimidines [123]. 
Altogether, deprivation of specific nutrients can be used as a strategy to study the molecular 
perquisites for the differentiation of the parasite. 
 
9. The Goal of Current Research 
Susceptibility to T. gondii infection varies between intermediate hosts. House mouse (Mus 
musculus) being more sensitive, variability in mouse virulence exists for different strains of T. 
gondii [1]. Thus, in order to study the virulence of strains of T. gondii, the house mouse is the 
preferred model.  Several studies have also shown that a correlation exists between disease 
severity in humans and mouse virulence [33]. However, when studying virulence in mice, many 
factors such as route of infection, life stage of the parasite, the number of passages of the parasite 
in mice or cell culture, and the mouse host line used gives rise to variable results. This 
inconsistency in the protocol makes the comparison of results between labs difficult. Thus, in 
chapter 1, we discuss important factors to be considered when conducting T. gondii murine 
virulence assays and propose a standardized methodology to facilitate the integration of T. gondii 
virulence data throughout the research community. This will enable more efficient and effective 
analysis of genetic and virulence patterns for this important parasite.   
        The most recent study performed to understand the diversity of T. gondii on a global scale 
has shown that the population structure of T. gondii is more complex than thought originally. 
This study showed that type II and III are the two dominant T. gondii lineages [36]. Despite the 
dominance of different strains in different regions in the world, type II stands out as the most 
dominant lineage globally. Furthermore, type II T. gondii was found to be most dominant in 
Europe compared to other regions like Africa, North America or South America. Additionally, 
congenital toxoplasmosis cases in Europe were caused by type II T. gondii [124]. Therefore, it is 
critical to understand the origin and transmission pattern of the type II lineage to other regions of 
the world. In order to study this, 299 type II samples were collected globally and analyzed to 
study the diversity among these isolates. Furthermore, the current population structure suggests 
that the second most dominant lineage, distributed globally, is the type III lineage of T. gondii 
[36]. Based on the mouse virulence studies, almost all the strains belonging to the type III 
lineage are avirulent and infections often result in the establishment of chronic infection in mice. 
This could be one explanation for the global spread of type III T. gondii. However, despite its 
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global spread, type III strains are more dominant in South America, and therefore, would be 
interesting to investigate whether type III MRCA originated in South America, or if it is 
transmitted and recently expanded in this region.  
        Toxoplasma gondii is a wide spread pathogen capable of infecting almost all warm-blooded 
animals [1]. One-third of the human global population is infected with T. gondii. As T. gondii 
can be transmitted to humans via consumption of contaminated meat, the study of the 
seroprevalence rate among the wildlife is of importance [2]. Furthermore, the resistance of 
wildlife to T. gondii favors the selection of more virulent strains [27, 28, 30]. Even though the 
number of epidemiological studies is increasing, the reports for seroprevalence rate in wildlife 
from certain regions have been limited. To, therefore, study the infection rate of T. gondii and the 
genotypes circulating among wildlife from the southeastern region of United States, we collected 
471 wildlife sera samples from six southeastern states namely, Tennessee, Kentucky, North 
Carolina, South Carolina, Alabama, and Georgia. 
        Even though several of the pathways discussed above that are known to control the 
bradyzoite differentiation/ maintenance have been studied, the master regulatory gene or 
pathway for developmental switching is still unknown.  As described previously, studies have 
predicted the possible genes/enzymes that contribute to bradyzoite differentiation under different 
stress conditions such as NO, heat stress and nutrient starvation [95, 119, 122]. Although these 
studies add to the pool of knowledge on type switching, they fail to establish a cohesive 
representation of genes necessary for bradyzoite conversion pathways. Our current 
understanding of genes involved comes from studying the conversion of tachyzoites to 
bradyzoite stage of the parasite which fails to paint the complete picture. In order to detect the 
main regulatory gene(s) or pathway(s), it is undeniably important to study the interconversion 
process between the two stages. A recent study using cDNA microarray analysis of tachyzoite to 
bradyzoite conversion defective mutants (TBD), predicted the hierarchy of genes involved in 
bradyzoite development [125]. This study supported the notion that multiple bradyzoites 
inducing conditions and stresses should have a common pathway/genes leading to the stage 
switching of Toxoplasma. In order to accurately characterize the most important genes, our 
future study will focus on identifying the gene(s) that plays a major role in the conversion of 
tachyzoites to bradyzoites and vice versa. The strategy involves the use of the physiologically 
relevant NO donor drug, SNP as the stress model and the subsequent use of RNA sequencing at 
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different time points throughout the interconversion process in vitro. This study focused on 
establishing an experimental setup for converting tachyzoites into bradyzoites and vice versa 
under external stress conditions. Further use of this experimental strategy could lead to the 
identification of gene(s) that occupy the key position(s) in the bradyzoite development pathway. 
This could be done by comparison of upregulated/downregulated genes over the time during 
differentiation to bradyzoites. The reverse should be true when parasites revert to the tachyzoite 
stage of the life cycle. 
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CHAPTER 1: ON THE DETERMINATION OF TOXOPLASMA GONDII VIRULENCE 
IN MICE 
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1. Abstract 
Toxoplasma gondii is one of the most successful pathogens on earth, capable of infecting an 
extremely broad range of mammals and birds and causing potentially fatal disease in humans. 
The house mouse (Mus musculus) has been used as the primary laboratory animal model for 
determining the virulence of T. gondii strains. Epidemiological evidence also suggests a potential 
association between virulence in mice and disease severity in human toxoplasmosis. However, 
many factors can affect virulence measurements, including route of infection, life stage of the 
parasite, number of passages of the parasite in mice or cell culture, and the mouse host line used. 
Variability among these factors makes it difficult to compare results between different studies in 
different laboratories. Here, we discuss important factors that should be considered when 
carrying out T. gondii murine virulence assays and propose a standardized methodology that 
should facilitate integration of T. gondii virulence data throughout the research community in 
future studies and thereby enable more efficient and effective analysis of genetic and virulence 
patterns for this important parasite.   
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2. Introduction 
 Toxoplasma gondii is an obligate intracellular parasite capable of infecting almost all warm- 
blooded animals, including humans [1].  Felids are the only known hosts, in which sexual 
reproduction of the parasite occurs, resulting in the dissemination of oocysts into the 
environment via defecation, and thus play a critical role in the transmission of T. gondii. It is 
estimated that one third of the world’s human population is chronically infected with this parasite 
[1]. Humans acquire infection by ingesting oocysts from contaminated food and water, 
consuming undercooked meat containing tissue cysts, or by vertical transmission from mother to 
fetus [1, 2]. The primary infection in immunocompetent individuals is mostly asymptomatic but 
in some cases it can lead to ocular toxoplasmosis [3]. In immunocompromised individuals, such 
as AIDS patients, reactivation of chronic infection can cause life threatening encephalitis [1, 4]. 
        Susceptibility to T. gondii infection varies among different hosts: cattle, horses, rats, Old 
World monkeys and humans are resistant to infection, while Australian marsupials and New 
World monkeys are much more susceptible. The reasons for such differences are not clear, but 
one reason may be a consequence of host-parasite co-evolution [1]. Laboratory mice are 
generally sensitive to T. gondii infection and are often used as the preferred animal model to 
determine the virulence of the parasite.  
        Virulence of T. gondii strains in mice varies with the genetic background of the parasites. 
Some genotypes of T. gondii are lethal to all strains of mice regardless of the dose of parasites 
administered, whereas other genotypes are non-lethal with a low dose of inoculation and can 
readily establish chronic infection in mice [10, 11, 124, 126, 127].  
        Recent analysis of T. gondii genetic diversity has revealed geographical patterns of 
genotype distribution [36]. Archetypal type II and type III strains are dominant in Europe and 
North Africa, while types II, III, and 12 are dominant in North America, and Chinese type 1 is 
most prevalent in East Asia. In contrast, T. gondii strains in South America are highly diverse 
with no clear dominance of any particular genotypes. The genotypes prevalent in Europe, North 
America, North Africa and Asia are non-lethal to mice at low infection dose, whereas a large 
proportion of T. gondii strains identified in South America are highly virulent and lethal to mice 
[126]. Population genetics and epidemiological studies have indicated a correlation between the 
geographic variations of T. gondii genotype and disease manifestation in humans. For example, 
severe symptoms associated with ocular toxoplasmosis are more frequently reported in Brazil 
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than in European countries [3, 128], and numerous incidences of severe systemic toxoplasmosis 
in immunocompetent adults from French Guiana have been reported, in some cases resulting in 
the deaths of the afflicted individuals [27, 28, 129]. Taken together, virulence of different T. 
gondii strains in mice appears to be generally correlated with disease manifestations in human 
cases [33]. Therefore, determination of T. gondii virulence in mice could be invaluable in 
predicting the potential outcome of human infections.  
         To obtain a better understanding of large-scale patterns of T. gondii virulence, it is essential 
to have a standardized methodology for parasite virulence determination which allows for direct 
comparison of the results obtained from different studies. Currently, a variety of mouse strains, 
different life cycle stages of the parasite, and different routes of inoculation are used in T. gondii 
virulence assays. This variation hinders meaningful comparisons and complicates integration of 
data. In order to address this issue, in this review we summarize the common methodologies 
used to determine T. gondii virulence in laboratory mice, and put forth a simple standardized 
methodology that will facilitate more productive comparisons for future studies. Establishment 
of a cohesive database for studying the relationship between T. gondii genotype and virulence in 
mice should greatly enhance our understanding of parasite virulence patterns and aid in 
predicting the outcome of T. gondii infection in humans. 
 
3. Current methods for virulence assessment of T. gondii in mice 
 
3.1 Virulence of tachyzoites, bradyzoites and oocysts of T. gondii 
Toxoplasma gondii has a complex life cycle, and the specific stages of the parasite used for 
inoculation may lead to marked differences in the outcomes of virulence in mice. The three 
infectious forms of the parasite include: the rapidly dividing tachyzoite, responsible for systemic 
invasion during primary infection; the slowly growing bradyzoite, associated with chronic 
infection; and the sporozoite, sexually produced in mature oocysts. All three forms may be used t 
o infect mice, but infection with different forms may have varied results in terms of virulence. 
For example, mice inoculated orally with a single oocyst of the strain M-7741 were found to 
exhibit 100% mortality after approximately two weeks, whereas 103 bradyzoite-containing tissue 
cysts were required to produce this same mortality rate, and mice infected orally with 104 
tachyzoites failed even to establish infection [130]. Higher pathogenicity of oocysts is also 
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evident from a previous study in which mice infected orally with 10 oocysts died within two 
weeks but mice orally infected with 10 tissue cysts failed to cause any infection [131].  Among 
the three infectious stages of the parasite, oocysts in general are more virulent [130-132]. In 
addition, oocysts are environmentally resistant, highly infectious, and thus hazardous to work 
with, whereas tachyzoites and bradyzoites are readily killed even in water. 
 
3.2 Change of T. gondii strain phenotypes after multiple passages in mice and cell culture 
Changes in biological characteristics occur in T. gondii strains after passage in mice or cell 
culture [127, 133-137].  Toxoplasma gondii strain M-7741, initially isolated from a sheep in 
1950, was found to have lost the capacity to produce oocysts in cats after 30-35 continuous 
passages in mice [134]. Similarly, after maintained in cell culture for 40 passages, the type I 
strain GT1 lost the ability to produce oocysts in cats [135]. The most commonly used T. gondii 
RH strain which was isolated from a six-year old child in 1939, has been found to no longer 
produce oocysts in cats following prolonged maintenance through passage in laboratory mice or 
cell culture, presumably due to unknown biological changes in parasites over time [137]. A 
variety of phenotypic changes among several RH-derived clonal lineages were also observed 
[127]. Differences among these lineages included larger plaque formation, enhanced survival 
outside the cells, faster growth, and decreased differentiation. Enhanced virulence in mice for T. 
gondii strains maintained in cell culture for several passages has been reported previously [138] 
In that study, 28 out of 31 original isolates from Costa Rica established asymptomatic infection 
in mice with only 3 isolates were highly virulent to mice. However, after five to ten passages, 7 
of the 31 isolates were highly virulent and killed the mice [138]. Genetic variability among RH 
lineages in different laboratories has been reported [139]; however, the cause-effect relationship 
between genetic variations and phenotypes is unclear. Taken together, previous studies 
highlighted the phenomenon of phenotypic changes during continuous passages in mice or cell 
culture. Therefore any comparison of phenotypes among T. gondii isolates should be conducted 
using the original or low passage stocks.  
 
3.3 Routes of infection and virulence of T. gondii  
The three common routes in determining T. gondii virulence in mice include intraperitoneal (IP) 
injection, subcutaneous (SC) injection and per oral inoculation [130, 140].  The IP injection 
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involves direct deposition of T. gondii parasites into the peritoneal cavity, whereas SC injection 
deposits the parasites below the dermis. In oral infections, parasites are deposited into the 
stomach of mice. Differences in infectivity and pathogenicity in mice have been observed 
between IP and oral route of infections with T. gondii [130]. Mice infected orally with 10 tissue 
cysts failed to establish infection, whereas the IP infection resulted in successful infection in 
33% of mice. In the same study, results for the SC inoculation were comparable to the IP 
injection [130].  Similar results were obtained in a separate study, wherein all mice orally 
infected with 100 tissue cysts of a T. gondii isolate survived, while all mice infected with same 
number of cysts by IP injection died an average of 12 days [131].  Another study showed that 
C57BL/6 mice were highly sensitive to oral infection, but resistant to IP injection [140]. As 
evident from these observations, the route of infection has an important effect on T. gondii 
virulence in mice and thus a standardized inoculation method is necessary in order for direct 
comparisons between different studies. 
 
3.4 Variable susceptibility of different mouse lines to T. gondii infection 
A high degree of variation in susceptibility to T. gondii has been observed among different lines 
of laboratory mice [140-143]. The DBA/1, DBA/2, BALB/c, C57B1/6J, B10.D2, SW/SIM  and 
C3H/Bi mice showed markedly different outcomes when infected IP with tachyzoites of the C56 
strain of T. gondii [141]. At a higher dosage (1x105 parasites), all DBA/2 and BALB/c mice died 
within 12 days of inoculation, all B10.D2 mice died within 18 days, and the other mouse strains 
showed mortality rates ranging from 60 to 90 percent at 30 days post infection. Outbred mice 
(SW/SIM) were considerably resistant, with only 67% mortality at day 30 [141]. Mouse-line 
dependent susceptibility was also observed in C57BL/6, LACA and BALB/c mice [140]. When 
10 brain tissue cysts were used for IP inoculation, LACA mice were highly sensitive, whereas 
C57BL/6 mice were resistant. However, by oral infection, the LACA mice were resistant and the 
C57BL/6 mice were sensitive. BALB/c mice were resistant to both routes of infection [140]. A 
more recent study observed that when oocysts were administered orally, the ME49 strain of T. 
gondii was more pathogenic for transgenic (KO, HLA3.11, HLA2.1 and Hlab7), inbred 
(C57/black and BALB/c) and outbred (SW) mouse lines in decreasing order [143]. It has been 
demonstrated that BALB/c mice had a higher mortality rate than that of CBA/Ca mice during 
acute infection; however, the inverse was true for chronic infection [142](. McLeod and others 
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observed differences among the inbred mouse strains (C57BL/6 and A/J) infected per orally with 
100 cysts of the ME49 strain [144]. C57BL/6 mice were found to be consistently susceptible, 
whereas A/J mice were resistant to infection. Susceptible mouse lines had a weakened 
gastrointestinal barrier, a lower splenic cytotoxic count, a weak IgM protective immune response 
and activation of Kupffer cells. To further investigate the differences between the 
aforementioned mouse lines (A/J and C57BL/6), McLeod and others studied the survival rates 
and brain cyst numbers of recombinant strains obtained by crossing the two lines, and found that 
survival was controlled by H-2 complex and a set of at least five genetic loci [145]. The H-2a 
haplotype was linked to resistance in a dominant manner, whereas the H-2b haplotype was found 
to be recessively associated with susceptibility. Mice with the H-2a haplotype were found to 
regulate the number of tissue cysts during chronic infection. Together, these studies demonstrate 
the strong effect that genetic variability of laboratory mouse lines has on their susceptibility to T. 
gondii infection. It illustrates the importance of selecting appropriate mouse lines with similar 
resistance when making virulence comparisons.   
 
3.5 Methods of preparing tachyzoites for infection 
Most studies on T. gondii virulence in laboratory mice have employed the tachyzoites due to its 
relative ease of preparation. The two most common ways of propagating tachyzoites include the 
use of mice and cell culture [1]. For the former, T. gondii bradyzoites, tachyzoites or sporozoites 
can be inoculated into the mice by IP injection. Within a week post infection, tachyzoites can be 
harvested from the peritoneal exudates in the abdominal cavities of mice [146].  Toxoplasma 
gondii strains that are highly virulent usually propagate well in mice and release a large amount 
of free tachyzoites within 3-7 days post infection.  However, T. gondii strains of low virulence 
usually replicate slowly and free tachyzoites are difficult to obtain. To overcome this problem, it 
is advisable to administer 10 µg/ml dexamethasone phosphate in drinking water, which will 
suppress the murine immune response and facilitate tachyzoites production [1].   
     In laboratories with access to cell culture, T. gondii tachyzoites can be propagated and 
maintained readily. Tachyzoites can proliferate in almost any mammalian cell lines, with 
fibroblasts being the most commonly used [147]. Whether obtained from cell culture or mouse 
peritoneal exudate, tachyzoites will often be mixed with a large amount of host cells. Therefore, 
it is necessary to remove these cells and enrich tachyzoites. There are several methods to purify 
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tachyzoites, including density gradients, sonication and trypsin digestion, differential 
centrifugation, hemolysin digestion, filtration through glass wool, cellulose columns or sintered 
glass, and polycarbonate filtration [146]. With the exception of sonication and trypsin digestion, 
all of these methods are capable of removing greater than 90% of the mouse leukocytes without 
altering parasite viability [146]. Recently, a comparison of tachyzoite purification by trypsin 
digestion, filtration by 3-µm polycarbonate membrane, filtration by CF-11 cellulose, and 
separation by percoll solution showed similar results [148]. Therefore, tachyzoites prepared by 
trypsin digestion should be avoided for virulence testing in mice. In our laboratory, purification 
by filtration through a 3-µm polycarbonate membrane is routinely conducted due to its ease of 
use.  
 
3.6 Dose-independent and dose-dependent mortality in mice   
Earlier studies of mortality in mice have shown that some T. gondii strains such as those 
belonging to the type I lineage are highly virulent to mice and kill all infected mice within two 
weeks after infection regardless of inoculation dosage [10, 149]. For these acutely virulent T. 
gondii strains, a single viable parasite is lethal to mice; therefore the mortality is dose-
independent. In contrast, the majority of T. gondii strains can readily establish chronic infection 
in mice if inoculated at low dosages, and mortality in mice is dose-dependent. The type II and III 
T. gondii lineages belong to this group [10, 12, 149, 150]. Therefore, to accurately determine the 
virulence of T. gondii strains, it is necessary to test a series of parasite concentrations ranging 
from low to high inoculation doses. Any single dose inoculation will not be able to appropriately 
assess the virulence of a particular T. gondii strain. 
 
4. Proposed methodology for virulence assessment of T. gondii in mice  
Virulence of T. gondii strains has been commonly defined by the mortality rate in laboratory 
mice. However, due to the lack of a standard method, comparing results among published reports 
is challenging. To make measurements of virulence of T. gondii in mice comparable across 
different studies, it is imperative to establish a standardized method. Examination of the 
cumulative mortality in mice infected via IP injection with serial dosages of tachyzoites is 
arguably the most suitable method for accomplishing this goal. This method has been previously 
used for the quantitative trait locus (QTL) analysis of T. gondii virulence determinants using 
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genetic crosses that led to the discovery of the major parasite virulence factor ROP18 [13, 14, 
151].  
     Here we propose a standard protocol to determine T. gondii virulence in mice (Figure 2.1): 
(1). Propagate low-passage T. gondii strains in mice or cell culture. If propagating in mice, 
administer 10 μg/ml dexamethasone in drinking water starting two days before inoculating 
the parasites to suppress mouse immune response. 
(2). Collect tachyzoites from a two-day passage of cell culture or from the peritoneal cavity 
of infected mice within 3-7 days of infection.  Purify tachyzoites by filtering through a 3-μm 
polycarbonate filter.  
(3). Collect the parasites in 15-ml centrifuge tube, centrifuge at 1000x g for 10 min at room 
temperature. Discard supernatant and resuspend the parasites in 5 ml phosphate-buffered 
saline (PBS).  
(4). Determine the concentration of tachyzoites using a hemocytometer.  
(5). Prepare ten-fold serial dilutions of 2x104 to 2x101 tachyzoites/ml using PBS.   
(6). IP or SC inoculate 500 µl of parasites to 5 outbred mice (CD-1, CF-1 or Swiss-Webster) 
for each dilution. Observe mice daily for four weeks. Euthanize severely ill mice.  
(7). Record daily mortality. For those mice survived the infection for 4 weeks, collect blood 
samples and determine seroconversion by modified agglutination test (MAT) test. The cutoff 
value for positive infection is 1:25.   
(8). Determine cumulative mortality in mice. To calculate cumulative mortality, three 
sequential inoculation dosages should be analyzed; with the lowest dose resulting in only 
partial infection of the mice (Table 2.1 and Table 2.2).  
Below is the suggested protocol for the MAT test. It is slightly modified from previously 
published protocol [1, 152].   
(1). Materials and reagents needed are: 1x PBS pH 7.2; alkaline buffer [7.02 g NaCl, 3.09 g 
boric acid, 24 ml of 1N NaOH, 4 g of bovine plasma albumin in 1 liter of distilled water, 
adjust pH to 8.7, add 1 g sodium azide (0.1% final) as a preservative, final pH 8.2-8.4];  
Toxoplasma whole cell antigen (RH strain prepared in cell culture, formalin-fixed, 2x108 
tachyzoites/ml); 2-mercaptoethanol;  Evans blue dye (2 mg/ml in H2O);  96-well U-bottom 
microtiter plate; positive serum control (1:200 titer); and negative serum control. 
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Low-passage T. gondii isolates 
Expand in mice Expand in cell culture 
Filter to purify tachyzoites 
Count parasite using hemocytometer 
Prepare serial dilutions of tachyzoites (2x10
4
 to 2x10
1
parasites/ml) 
IP or SC injection to 5 outbred mice for each dose,  
observe for 4 weeks 
MAT test of the survivors 
Determine accumulative mortality 
Figure 2.1: Proposed methodology to test virulence of T. gondii strains in mice. 
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Table 2.1: Calculation of cumulative mortality rate (Example 1). 
 
Dosages 
Mice 
survived 
Mice 
seronegative 
Mice 
seropositive 
No. mice 
died 
No. mice 
infected 
1x104 1 0 1 4 5 
1x103 3 0 3 2 5 
1x102 4 2 2 1 3 
1x101 5 5 0 0 0 
 
The number of mice injected per group is 5. 
The dosages 1x104, 1x103, and 1x102 will be included for calculation. The cumulative mortality 
is calculated based on the number of mice died divided by the number of mice infected. The 
number of infected mice includes mice that have died and surviving mice that are MAT test 
positive. The cumulative mortality for this example is (4+2+1) / (5+5+3) = 7/13 = 54%. 
 
 
 
 
 
 
 
 
 
 
 
   
 
33 
 
Table 2.2: Calculation of cumulative mortality rate (Example 2). 
 
Dosages 
Mice 
survived 
Mice 
seronegative 
Mice 
seropositive 
No. mice 
died 
No. mice 
infected 
1x104 0 0 0 5 5 
1x103 0 0 0 5 5 
1x102 2 1 1 3 4 
1x101 4 3 1 1 2 
 
The number of mice injected per group is 5. 
The dosages 1x103, 1x102, and 1x101 are included for calculation. The cumulative mortality is 
(5+3+1) / (5+4+2) = 9/11 = 82%. 
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(2). Mix 3.0 μl of serum sample with 72.0 μl PBS (1:25 dilution).    
(3). Transfer 50 μl of diluted serum samples to the first row a U-bottom 96-well microtiter 
plate (10 samples, plus one negative and one positive controls). 
(4). Add 25 μl of PBS to the rest of wells using multichannel pipette.  
(5). Make serial dilution to 1:3200 for each serum samples including the negative and 
positive controls. Discard the last 25 μl of diluted serum samples. 
(6). Prepare antigen mixture (for each 96-well plate) by mixing the following reagents: 2.5 
ml alkaline buffer, 35 μl 2-mercaptoethanol, 50 μl Evans blue dye (2 mg/ml in H2O), and 150 
μl T. gondii MAT antigen.  
(7). Mix antigen well by pipetting, immediately transfer 25 μl to each well using 
multichannel pipette.  
     (8). Cover the plate with sealing tape and incubate at 37°C for 16 hours (overnight) Read 
results. A pellet at the bottom of the well means negative. Samples without pellets are positive. 
 
5. Future perspective 
In recent years, two highly polymorphic rhoptry proteins (ROP18 and ROP5) have been 
identified as the major virulence determinants in T. gondii [13-15, 22].  Together, the ROP18 and 
ROP 5 play a role in the suppression of host innate immune response via formation of a complex 
with murine immunity related GTPases, preventing destruction of the parasitophorous vacuole 
[15, 21, 22]. Recently, using PCR-RFLP technique, it was shown that ROP18 and ROP5 allele 
types are associated with the virulence of T. gondii in mice [126].  Therefore, we suggest 
performing the above in vivo virulence test in mice and the genotyping test of ROP18 and ROP5 
in parallel in the future. Over time, this will accumulate a large data set to further evaluate the 
strength of the association between virulence in mice with the genotypes of ROP18 and ROP5 
genes. If a strong association is confirmed, then genotyping of these genes can be used as a 
simple test to predict T. gondii virulence in the future.   
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CHAPTER 2: TO REVEAL THE MOST RECENT ANCESTOR AND TRANSMISSION 
PATTERN OF TYPE II LINEAGE OF TOXOPLASMA GONDII 
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1.Abstract 
Toxoplasma gondii is one of the most successful pathogens on earth, capable of infecting all 
mammals and birds. Recent population genetics studies in T. gondii revealed low diversity in 
North America, Europe, Africa and Asia but high diversity in South America. Among the many 
genotypes identified so far, the type II lineage is widespread and dominant in Europe. To 
elucidate the most recent ancestor (MRCA) of type II and to study its transmission pattern, we 
genotyped 296 type II isolates using 15 microsatellite markers. Our results showed that the type 
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II strains from Europe have the highest diversity, followed by those from Africa, South America, 
and North America. Type II isolates from North America are largely clustered together to the tip 
of the phylogenetic tree. These results suggest that the MRCA of type II T. gondii may have 
originated from Old World (Europe or Africa), and expanded and transmitted globally in the past 
several hundred years. 
 
2. Introduction 
Toxoplasma gondii is the most successful zoonotic pathogen known today [1].  It has a complex 
life cycle that propagates sexually in a definitive host (cats) and asexually in the intermediate 
host (mammals and birds) [1]. Cats contaminate the environment by shedding T. gondii oocysts 
in the feces. Both intermediate and definitive hosts can acquire the infection by oral ingestion of 
oocysts from the environment, oral ingestion of tissue cysts in contaminated meat from infected 
animals or by transplacental transmission via tachyzoites. One-third of people are chronically 
infected worldwide [1, 153]. Infection in humans can cause ocular, congenital, or severe acute 
disseminated toxoplasmosis. In immunocompromised patients, reactivation of latent infection 
can cause life-threatening encephalitis [4].  
        Early genotyping studies on 106 isolates from Europe and North America using 6 PCR-
RFLP markers divided T. gondii isolates into three clonal types denoted as types I, II and III. The 
three archetypical lineages of Toxoplasma showed variability in mouse virulence [10, 11]. 
Isolates belonging to type I were found to be highly virulent causing mortality during the acute 
phase of infection even at very low doses [10, 12]. Type II and III strains cause chronic 
infections at lower dosages. However, type II strains at moderate dosages can cause mortality in 
mice [11].  The most recent data on diversity structure of Toxoplasma have been obtained from a 
study carried on 1457 isolates using 10 PCR-RFLP markers. A total of 189 haplotypes were 
found from 1457 isolates of T. gondii collected worldwide. Use of these markers revealed that 
the type II strain is most dominant worldwide and comprises of 64.1% of the T. gondii 
population in Europe compared to 45.4% and 43.9% in Egypt and North America respectively 
[36]. Previously, type II has also been linked with congenital toxoplasmosis in Europe [124]. 
Even though type II is the most dominant clonal lineage of T. gondii worldwide, little is known 
about its origin or transmission.  
   
 
38 
 
      Based on use of 10 PCR-RFLP markers all the strains included in this study are considered to 
be type II with little genetic variability. However, use of markers designed for microsatellite 
regions gives a higher discriminatory power to differentiate isolates belonging to the same 
lineage. Microsatellite regions are found in eukaryotes with a mutation rate of 10-2 to 10-5, which 
is 1000 times higher than the SNPs. The MS regions undergo length polymorphism as a result of 
strand slippage process during DNA replication. The number of repeat units differs due to 
addition or deletion, thus creating multiple alleles at an MS locus [154]. In this study, we utilized 
15 previously designed microsatellite markers to obtain a better genetic differentiation among the 
299 type II isolates available from around the world [155]. In this work, we attempted to 
comprehend the diversity of type II T. gondii strains and track its transmission on a global scale. 
The genetic variability among the type II isolates collected from different geographical regions 
can shed some light on the origin and the transmission pattern of the type II clonal lineage of T. 
gondii. We also discuss the factors such as agriculture and European expansion that may have 
played a role in the transmission and expansion of type II in the last few hundred years.  
 
3. Materials and Methods 
 
DNA samples 
DNA samples were collected from previous studies in our laboratory (Table 3.2 and Table 3.2) 
[36]. Information about the location and host for these isolates were obtained from previously 
published papers. DNA for all the isolates was either obtained from heart or brain tissues of 
experimentally infected mice or tissue culture. Ethiopian feral cat isolates (n=14) included in our 
study were collected from feral cats from Addis Ababa region in Ethiopia [156]. Egyptian feral 
cat samples (n=26) were also isolated from Abourawash, Giza, Egypt [157].  Egypt dog samples 
(n=8) were obtained from stray dogs supplied by a contractor from the region of Abourawash, 
Giza, Egypt [158]. One Mali chicken sample was obtained from an infected chicken collected 
from Mali [159]. Isolates from Norway fox (n=6) from the continent of Europe were obtained 
from an arctic fox (Vulpes lagopus) population from the high arctic archipelago of Svalbard[160]. 
Samples from Austria (n=30), Portugal (n=4) and Israel (n=4) included in our study were 
obtained from free range/backyard chickens [161]. T. gondii isolates from pigs (n=16) were all 
derived from adult pigs (sows) from Iowa [162]. Samples collected from Maryland (n=19) were 
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isolated from lambs from a slaughter house in Baltimore, Maryland [163]. Lambs were between 6 
to 12 months old and were raised in Maryland, Virginia and West Virginia. One sample from 
New Jersey was obtained from a white-tailed deer during the 2011-2012 hunting season. Samples 
acquired from Brazil (n=2) were collected from sheep from two slaughter houses in Botucatu 
region, Sao Paulo state [164]. T. gondii DNA samples obtained from Chile (n=16) were collected 
from naturally infected chicken from rural farms spread around 85 different properties [165].  
Four samples (PSC, 3440, FUN and CHA) included in this study were obtained from different 
AIDS patients with acute toxoplasmic encephalitis [11]. Two samples (DEG and Tg132) were 
obtained from non-AIDS- related human infections [11]. One sample was isolated from sheep 
from the Huzhu city of Qinghai province of China [166]. The information of hosts and location 
for previously unpublished samples are included in the study (Table 3.2 and Table 3.3).  
 
Genotyping with MS markers 
Genotyping of T. gondii isolates was performed using 15 MS markers located on 11 different 
chromosomes in a single multiplex PCR reaction [155].  Primers were used at the working 
concentration of 29.4 μM, except primers B18, N82, AA, and XI.I. Markers B18 and N82 had 
more PCR products than other markers; therefore, the concentration was reduced to 17.64 μM. 
Alternatively, markers AA and XI.1 had significantly less PCR product and so the concentration 
in the multiplex mix was increased to 82.3 μM and 58.82 μM respectively. The microsatellite 
sequences were amplified by multiplex PCR carried out in 25 μl reactions using the reagents 
provided in a Qiagen multiplex PCR kit in 96 well plates. Non-type II reference strains included 5 
isolates; GT1 (type I, ToxoDB PCR-RFLP genotype #10), CTG (type III, ToxoDB  genotype #2), 
MAS (ToxoDB genotype #17), TgCgCa1 (ToxoDB genotype #66) and TgCatBr5 (ToxoDB 
genotype #19). A PCR reaction without DNA was used as a negative control to check for any 
DNA contamination during the procedure. PCR products were diluted in deionized formamide 
and the dilution factor was optimized based on the quantity of PCR product estimated from 
running a 2.5% agarose gel. 1µl of each diluted PCR product was mixed with 0.5 µl of a dye-
labeled internal size standard (ROX 500; Applied Bio-systems) and deionized formamide [155]. 
This mixture was later denatured and electrophoresed using an automatic sequencer (3730 DNA 
analyzer; Applied Bio-systems). The size of the base pairs was determined using Peak-Scanner 
analysis software (version 2.0; Applied Bio-systems).   
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Data analysis 
The multilocus microsatellite typing data was coded for all genetic loci. For a given locus, the 
DNA banding pattern was coded with a string of 1s and 0s. Phylogenetic network and neighbor- 
joining tree were generated by SplitsTree 4.8 [167]. A network tree was generated for 433 
samples that included 296 type II and 139 non-type II samples collected from different regions of 
the world (Table 3.2). Additionally, a rooted NJ tree for 301 samples (296 type II + 5 non type II 
as outgroup) was constructed using Fig tree v1.4.2 (Andrew Rambaut, Institute of Evolutionary 
Biology, University of Edinburgh, 2006) (Table 3.3). Basic statistics for quantitative gene 
diversity within populations were calculated using Arlequin v 3.5 [168] (Table 3.4). 
 
4. Results 
In the phylogenetic network tree generated for 435 samples, type II samples (n=296) were found 
to be clustered together. Non-type II samples (n=139) were found clustered with longer branch 
lengths (Table 3.1  and Figure 3.1).  A total of 296 type II T. gondii isolates were analyzed by 
15 Microsatellite markers (Table 3.3). These samples were divided into five regional groups, 
including  Africa (n=59), Europe (n=116), North America (n=99), South America (n=18), and 
others (n=4).  The majority of these samples were reported in previous publications (Table 3.3 
and Figure 3.2) [36]. Based on PCR-RFLP typing results, all 296 samples belong to the Toxo 
DB genotype #1 or # 3 that together are considered to be type II.  Five non-type II samples; 
including GT1 (type I), CTG (type III), MAS, TgCrCa1 and TgCatBr5 (atypical) were included 
as an outgroup for phylogenetic analysis. 
        In total, 205 unique microsatellite (MS) types were identified among the 296 type II 
samples (Table 3.3). This includes 90 MS genotypes from 116 European isolates, 43 MS 
genotypes from 59 African samples, 2 MS genotypes from 4 Asian isolates, 59 MS genotypes 
from 99 North America isolates, and 11 MS genotypes from 18 South America isolates. Overall, 
samples from the same geographical region appear to cluster together. 
        The branch length for the European type II isolates appeared to be much longer in 
comparison to isolates from other regions (Figure 3.2). Four samples collected from Germany 
(D15875, D15891, 3440 and PSC) were found to be quite different from other isolates from the  
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Color Type of T. gondii 
Red Type II (n=296) 
Black  Non-type II (n=139) 
 
Figure 3.1: Phylogenetic network tree constructed for 435 isolates of T. gondii using Splits 
tree v 4.3.1. 
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Figure 3.2: Rooted tree for 285 isolated of T. gondii analyzed with 15 microsatellite 
markers constructed using Fig tree v1.4.2. 
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Figure 3.2 (continued) 
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Figure 3.2 (continued) 
 
 
  
Color Region 
Purple Europe (n=116) 
Green North America (n=99) 
Orange South America (n=18) 
Red Africa (n=59) 
Blue Others (n=4) 
Black Non-type II (n=5) 
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Table 3.1: Location and frequency of samples for 296 types II T. gondii isolates. 
 
Region of T. gondii isolate Number of Samples 
Ethiopia 14 
Egypt 35 
Mali 1 
South Africa 9 
France 43 
Austria 30 
Portugal 13 
Belgium 9 
Norway 7 
Israel 4 
Romania 2 
Germany 19 
England 1 
UK 1 
Iowa 16 
NewEngland 20 
Maryland 
 
19 
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Table 3.1 (continued) 
Region of T. gondii isolate Number of Samples 
Illinois                                                                    
Cleaveland 
11 
19 
USA 10 
Minnesota 5 
Wisconsin 4 
Grenada 2 
Colorado 1 
Chile 16 
Brazil 2 
China 1 
Japan 2 
Australia 1 
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European continent. These samples appeared to be separated from the European cluster and were 
embedded into the cluster of North American isolates. 
In Africa, a total of 59 samples had 43 unique genotypes. The branch lengths appeared to be 
longer when compared to North American isolates. Samples from  North Africa (Ethiopia and 
Egypt) were found to be quite diverse and were distributed within the European isolates. On the 
other hand,  isolates from South Africa were found to be clustered together (Figure 3.2). Overall 
the diversity of samples from Africa was comparable to European isolates. 
        In North America there appeared to be a high degree of genetic uniformity. Out of 99 
samples obtained, 59 unique genotypes were identified. Despite the diverse sampling of isolates, 
branch length appeared to be shorter and samples were clustered together forming an ingroup 
within the old world isolates of Europe and Africa. A few isolates from Cleveland (G25/M291, 
G22/M277, G191/M329, TX618G237M574, and TX618G658MNTKO) and Iowa (P35, P52 and 
P54) were separated from the North American cluster and were emebedded within European 
isolates (Figure 3.2).  
        Even though the available South American isolates were limited (n=18), the diversity was 
reasonably high, with 11 unique genotypes identified. Samples  from Chile and Brazil were also 
found to be rooted within Old World isolates but did not belong to one cluster. Rather, isolates 
were divided into several groups dispersed within the Old World samples (Figure 3.2).  
The diversity within Type II T. gondii populations from different geographical areas was 
quantified using Arlequin v 3.5 [168]. The results are summarized in (Table 3.4). The gene 
diversity observed among the four populations from high to low was in the following order; 
Europe > Africa > South America > North America.  
 
5. Conclusions 
The compiled microsatellite genotyping results for 296 isolates revealed high genetic diversity 
for isolates from Europe and Africa in comparison to the New World isolates from North and 
South America (Figure 3.2 and Table 3.3). In addition, all type II strains from North and South 
America shared common relatives towards the Old World isolates. Thus, our findings indicate 
that the most common recent ancestor (MCRA) of the type II T. gondii may have originated from 
the Old World (Europe and Africa) and likely to have transmitted to the New World (North and 
South America) from the Old World. Understanding the origin and transmission of the type II 
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lineage is of interest as it is most dominant lineage spread globally, and knowledge gathered 
from the study on this lineage may provide information regarding the spread of other zoonotic 
diseases. 
        In the network tree generated for 433 isolates, type II samples clustered at one end of the 
phylogenetic tree with smaller branch lengths, indicating that type II samples may have 
experienced recent expansion (Figure 3.1). A large number of unique MS genotypes (n=90) 
were found among type II samples (n=116) collected from diverse locations in Europe. Further, 
the phylogenetic rooted tree for the type II samples showed deeper branch lengths for the 
European isolates and situates European samples in an ancestral position (Table 3.3 and Figure 
3.2). This suggests that type II isolates from Europe are older. Moreover, quantitative 
comparison of genetic diversity among the four populations also revealed an overall higher 
(0.3686 ±  0.1975) diversity for the European isolates (Table 3.4). Similar to the European 
isolates, the branch length and average gene diversity per locus (0.3504± 0.1903) was found to 
be high for African isolates. Together, these results suggest that the MRCA for type II T. gondii 
may have originated in the Old World, comprised of Europe and Africa (average gene diversity 
of 0.3775 ± 0.2012). In addition to the shorter branch lengths and lower gene diversity (0.2632 ± 
0.1469), the majority of isolates from North and South America appeared to be embedded within 
the Old World isolates suggesting that type II may have transmitted from the Old World 
continents to the New World of America. Several major factors could have played a role in the 
transmission of type II lineage. Agriculture began approximately 11,000 years ago in the fertile 
crescent area near Europe and Africa [169]. Agriculture as an occupation conferred enormous 
advantages to farmers, and this resulted in expansion and dispersal of the farming population 
[170]. This is also reflected in a sudden rise in the human population during this period. 
Agriculture leads to an increase in the availability of grain crops that attract house mice and cats, 
which in turn increases their population density and proximity humans [171, 172]. Altogether, 
the advent of agriculture could have served as a factor in the expansion of T. gondii in Europe 
and Africa. Furthermore, European expansion (approximately within the last 500 years) may 
have introduced type II to the new world via maritime trading of goods, transportation of pets 
(including cats), slave trade routes, or accidental transport of infected rodents from Europe [173]. 
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Table 3.4: Basic statistics for type II T. gondii populations from different geographical 
regions. 
Due to small sample size of only four isolates; samples from Japan (2), China (1), and Australia 
(1) were not included in analysis. 
                                               
 
 
 
  
Europe 
 
Africa 
 
North 
America 
 
South/Central 
America 
 
Old 
World 
 
New 
World 
Number of isolates 116 59 99 18 175 117 
Number of MS 
genotypes 
90 43 59 11 133 70 
Average 
Gene diversity                 
0.3686  
±0.1975 
0.3504 
±0.1903 
0.2193 
± 0.1259 
0.2641 
± 0.1544 
0.3775 
± 0.2012 
0.2632 
± 0.1469 
                Africa 
             Europe 
North America 
South America 
        Old World 
      New World 
 
   
   
   
   
   
 A
fr
ic
a 
   
   
   
   
 E
u
ro
p
e
 
N
o
rt
h
 A
m
e
ri
ca
 
So
u
th
 A
m
e
ri
ca
 
   
   
  O
ld
 W
o
rl
d
 
   
   
N
e
w
 W
o
rl
d
 
 
+  + 
+ 
+ 
+ 
+ 
 
+ 
+ 
+ + + 
 
+ 
+ 
 
+ 
+ 
 
+ 
+ 
+ 
- 
- 
- 
- - 
- 
- 
- 
- 
   
 
50 
 
The genetically clonal population of type II isolates in North America could also be attributed to 
the ‘Founder Effect’. A change in landscape owing to the encroachment of forest areas for the 
purpose of farming leads to the replacement of wild animals by domestic animals [173]. This 
combined with the agricultural revolution may have led to the expansion of a limited number of 
successful strains from Europe, eventually reducing their diversity. In contrast to North 
American isolates, which cluster together, isolates from South America appeared to be spread 
within the Old World cluster and showed a higher gene diversity over loci. This suggests that 
transmission of isolates to South America from the Old World may have occurred several times 
independently. From the limited number of samples available from South America for this study, 
the majority were derived from Chile. The west coast of Chile is encompassed by the Pacific 
Ocean which serves as the major body of water used for the transportation of goods [36]. The 
maritime transport and travel between the continents could have served as the medium for 
multiple events of type II T. gondii transmission from Europe and could also explain the high 
diversity of isolates seen in South America [174]. Another possible explanation could be the 
dominance of wild animals in areas like the Amazon forest which serves as the hotspot for the 
diversity of T. gondii [175]. The expansion of human populated areas could result in a spillover 
of diverse type II strains from wildlife species leading to higher recombination rates and 
genetically diverse populations. However, the limitation of our samples to human environments 
fails to support the latter hypothesis. Better sampling from wildlife areas, as well as human-
dominated areas, is required in the future to draw a better conclusion for the higher diversity 
observed in this region.  
 
6. Future Perspectives  
Our current study reveals that the MRCA for type II T. gondii exists in the Old World and that 
type II is likely to have transmitted to the New World (America) from the Old World (Europe 
and Africa). However, little is known regarding the origin of other clonal lineages (type I and 
III). Thus, it will be interesting to further study the origin for other types of T. gondii and 
determine whether the transmission pattern appears to follow the pattern of type II clonal 
lineage. Based on our study, agriculture could be predicted as the main cause of transmission; 
however, our understanding of the role of migratory birds and animals is limited. In some 
regions like Brazil, pigeons can be infected with the parasite on a large scale and may thus play a 
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critical role in the transmission in regions with large populations of the migratory birds. Other 
species like sea otters and dolphins are also known to be infected and may play a role in the 
transmission of T. gondii as well [219]. Therefore, in order to obtain a deeper understanding of 
other factors, sampling from different hosts is necessary. This will also lead to a better 
understanding of the transmission and evolution of other zoonotic pathogens. A recent study by 
Mercier showed that human environments play a role in decreasing the diversity of T. gondii 
isolates [175]. As the human population continues to rise, it will be fascinating to unearth and 
predict the diversity structure of T. gondii in the coming future. The current global diversity 
structure of T. gondii shows the dominance of certain types in different pockets of the world. It 
will be of interest to unravel the factors behind this dominance in order to gain a better insight 
about the important host or players in different regions of the world. In the future, this 
knowledge will aid in controlling the spread of T .gondii in different regions of the world in the 
event of an epidemic.   
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CHAPTER 3: TO REVEAL GLOBAL TRANSMISSION OF TYPE III TOXOPLASMA 
GONDII LINEAGE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
53 
 
      Pooja Sarafa, J.P.Dubeyb and Chunlei Sua 
 
a. Department of Microbiology, The University of Tennessee, Knoxville, TN 37996. USA. 
 
b. Animal Parasitic Diseases Laboratory, United States Department of Agriculture, 
Beltsville, MD 20705, USA 
 
 
1.Abstract 
Toxoplasma gondii is one of the major zoonotic pathogens infecting a third of the world 
population. Previous studies have shown that population of T. gondii in northern hemisphere is 
clonal, whereas many genotypes co-exist in the southern hemisphere. Despite the diversity in 
South America, a large proportion of genotypes belong to type III lineage of T. gondii. Thus, to 
unveil the origin and transmission pattern of type III lineage, genotyping for 15 microsatellite 
markers was carried out for a total of 128 isolates. Furthermore, to study the expansion time, 
Microsatellite (MS) data for type II and type III (n=437) was analyzed. Out study revealed that 
type III lineage most recent common ancestor (MRCA) belongs to the New World and may have 
disseminated from the New World (America) to the Old World (Europe and Africa).  
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2. Introduction 
 The current population structure suggests that type III lineage of T. gondii is the second most 
dominant lineage found globally [36]. Based on the mouse virulence studies, almost all the 
strains belonging to type III lineage are avirulent and infections often result in establishing a 
chronic infection in mice [10, 12]. Previous studies showed that type III lineage is wide spread 
and frequently isolated in South America, which is in striking contrast to the most dominant type 
II lineage. Thus, it would be interesting to investigate global transmission pattern of type III 
lineage, and potential factors that facilitate its transmission.  
 
3. Materials and Methods 
 
DNA samples for MS analysis 
DNA samples were collected from previous studies in our laboratory [36]. Location and host 
information for these isolates were obtained from previously published papers (Table 4.1). DNA 
for all the isolates was either obtained from the heart or brain tissues of experimentally infected 
mice or cell culture.  A total of 137 type III isolates were collected from 13 mammalian species; 
including badger, bear, cat, chicken, dog, deer, dove, goat, goose, human, mongoose, sheep and 
white-tailed deer. The isolates belong to five regions; including Africa(n=48), Europe(n=7), 
North America(n=57), South America(n=16), Central America(n=9). 
 
Genotyping using 15 MS markers 
Genotyping of T. gondii isolates was performed using 15 MS markers located on 11 different 
chromosomes in a single multiplex PCR reaction [155].  Primers were used at the working 
concentration of 29.4 μM, except primers B18, N82, AA, and XI.I. Markers B18 and N82 had 
more PCR product than other markers; therefore, the amount was reduced to 17.64 μM. On the 
other hand markers AA and XI.1 had less PCR product and therefore their concentration in the 
multiplex mix was increased to 82.3 μM and 58.82 μM respectively. The microsatellite sequences 
were amplified by multiplex PCR carried out in 25 μl reactions using the reagents provided in a 
Qiagen multiplex PCR kit in 96 well plates. Non-type III reference strains included 5 isolates; 
GT1 (ToxoDB PCR-RFLP genotype #10, type I), PTG (ToxoDB genotype #1, type II), MAS 
(ToxoDB genotype #17), TgCgCa1 (ToxoDB genotype #66) and TgCatBr5 (ToxoDB genotype 
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#19). A PCR reaction without any DNA was used as a negative control to check for any DNA 
contamination. PCR products were diluted in deionized formamide and the dilution factor was 
optimized based on the quantification of the PCR products estimated from running a 2.5% 
Agarose gel. 1 µl of each diluted PCR product was mixed with 0.5 µl of a dye-labeled internal 
size standard (ROX 500; Applied Bio-systems) and deionized formamide. This mixture was later 
denatured and electrophoresed using an automatic sequencer (3730 DNA analyzer; Applied Bio-
systems). The size of the base pairs was determined using Peak-Scanner analysis software 
(version 2.0; Applied Bio-systems).   
 
Data analysis 
The multilocus microsatellite typing data for 123 type III isolates was coded for all genetic loci. 
For a given locus, the DNA banding pattern was coded with a string of 1s and 0s. Phylogenetic 
network and neighbor joining tree were generated by SplitsTree 4.8 [167]. A rooted NJ tree was 
constructed for 142 samples (137 type III + 5 non-type III as outgroup) using Fig tree v1.4.2 
(Andrew Rambaut, Institute of Evolutionary Biology, University of Edinburgh, 2006). A rooted 
phylogenetic tree was generated using the non-type III reference strains as outgroup. Similarly, a 
neighbor joining tree based on MS data was constructed for 437 (137 type III + 296 type II + 4 
outgroups) isolates. Basic statistics for quantitative gene diversity within populations were 
calculated using Arlequin v 3.5 [168]. 
 
4. Results 
 Based on the MS data, a rooted phylogenetic tree was constructed for type III isolates (n=123) 
using 5 non-type III isolates as the outgroup (Figure 4.1).  No geographical clustering of isolates 
was observed for type III lineage isolates. Irrespective of the location or host, branch length 
appeared to be more or less similar for all the isolates indicating similar divergence time. This 
was also evident when the number of unique genotypes within each population were found to be 
comparable. Furthermore, isolates from Central America were placed at the basal position, close 
to the root.  
        To compare relative expansion time between type III and type II lineages, neighbor joining 
network tree was constructed for 437 isolates; including 123 type III + 296 type II + 18 
outgroups (Figure 4.2 and Table 4.2).  
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Figure 4.1: Phylogenetic rooted tree constructed for type III (n=123) T. gondii isolates. 
 
Color Region 
Purple Europe (n= 6)  
Green North America (n=30) 
Orange South America (n=6) 
Red Africa (n=48) 
Blue Others (n=31) 
Black Non-type II (n=5) 
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Figure 4.2: Phylogenetic neighbor joining tree (NJ) tree constructed for 437 T. gondii 
isolates (123 type III + 296 type II + 18 outgroup). 
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Figure 4.2 (continued) 
 
Color Region 
Purple Europe  
Green North America 
Orange South America 
Red Africa 
Blue Others 
Black Non-type II (outgroup) 
Type III 
Type II 
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Table 4.3: Basic statistics for type III T. gondii populations from different geographical 
regions. 
Due to small sample size; samples from Europe and South America were not included in 
analysis. 
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It was observed that type II and III isolates formed two distinct clusters, different from the 
outgroups. Overall, type III lineage was less diverse than the type II lineages. However,  the 
overall branch lengths of type III strains was similar to that of type II strains in North America 
type II isolates from North American were clustered together comparison to type III isolates. 
Type III isolates from North America were distributed within the type III population and lacked 
clustering (Figure 4.2).  
 
5. Conclusions 
We examined genetic diversity of the type III lineage by microsatellite analysis. Our results 
suggest that the MRCA of type III lineage is likely originated in the New World and in recent 
history, this lineage has been rapidly radiated to the Old World. Given that neighbor-joining tree 
for 123 type III strains showed no association of genotypes with geographical locations,  the type 
III lineage may have spread from New World to the Old World many times independently in 
recent history. This intense transmission could be explained by the fact that most type III strains 
are avirulent to house mice. This may enable them to readily establish chronic infection in house 
mice and be efficiently transmitted in the house mice – domestic cats life cycle. Furthermore, 
Central America isolates placed near the root also suggests that the isolates from this region are 
older and may speak for the origin of type III in this region (Figure 4.2). 
        NJ tree constructed for combined data for type II and III isolates showed some interesting 
results for North American isolates. The obvious difference in topology between North American 
isolates clusters suggests that unlike type II North American strains, type III isolates have been 
transmitted to North America in multiple independent events. The most surprising information 
based on our results was the fact that type III transmission from the New World to the Old World,  
is opposite to that of type II lineage. The difference in the dissemination pattern for the two most 
dominant lineages suggests that these lineages may have undergone different selective pressures 
in the history of evolution. It is possible that dated back, type II may have migrated from the Old 
World to the New World, however in recent times the modern day type III strains maybe able to 
outcompete the type II strains and are being transmitted to the Old World. Our genetic analysis 
showed that type III strains from America are placed closer to the root of the phylogenetic tree, 
whereas samples from Africa and Europe are closer to the tip of the branches. A previous study 
suggests the type III lineage was a recombinant from ancestral type II and type III lineages [220]. 
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Such recombination may provide the modern day type III lineage selective advantages. One 
biological trait that could attribute to the widespread of type III strain is that they are non-virulent 
to house mice, which may allow them to be easily transmistted by the domestic life cycle with  
house mice (mus musculus) and cats (Felis). Therefore, it can be expected type III will further 
expand and potentially become the most dominant lineage globally in the future.  
 
6. Future Perspectives 
Given that T. gondii can infect a variety of host species including mammals and birds, and 
different hosts may contribute at different levels to the transmission of this parasite, predicting 
the direction of evolution of T. gondii will be challenging. However, future studies focusing on 
ecology of T. gondii infection, together with mathmatical modeling, will help us to better 
understand the main animal species and environmental factors that influence spread of this 
parasite, providing us necessary information to control or reduce transmission of T. gondii in 
humans. 
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CHAPTER 4: TOXOPLASMA GONDII SEROPREVALENCE AND GENOTYPE 
DIVERSITY IN SELECT WILDLIFE SPECIES FROM THE SOUTHEASTERN 
UNITED STATES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
63 
 
Richard W. Gerhold1, 2, Pooja Saraf3, Aly Chapman1, Xuan Zou3,   Graham Hickling2 and 
Chunlei Su3, 4 
1 Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, The 
University of Tennessee, Knoxville, TN 37996 
 2Center for Wildlife Health, Department of Forestry, Wildlife, and Fisheries, the University of 
Tennessee, Knoxville, TN 37996  
3Department of Microbiology, the University of Tennessee, Knoxville, TN 37996 
4Corresponding author (e-mail: csu1@utk.edu)  
 
1. Abstract   
Background: Toxoplasma gondii is a wide spread protozoan parasite that infects humans and 
other animals.  Previous studies indicate some genotypes of T. gondii are more frequently 
isolated in wildlife than agricultural animals, suggesting a wild/feral animal diversity model. To 
determine seroprevalence and genetic diversity of T. gondii in southeastern US wildlife, we 
collected sera from 471 wild animals, including 453 mammals and 18 birds between 2011 and 
2014. These serum samples were assayed for T. gondii infection using the modified agglutination 
test (MAT). Heart or tongue tissues from 66 seropositive animals were bioassayed in mice and 
19 isolates were obtained.  The isolated parasites were genotyped by the PCR-RFLP method 
employing 10 genetic markers. 
Results: One hundred and ninety-six of the 471 samples (41.6%) had a titer ≥ 1:32 and were 
considered positive for T. gondii infection. Of the 453 mammals, 195 (43%) were seropositive, 
whereas only one (5.6%) of the 18 birds was seropositive. Mammalian hosts with adequate 
samples size (≥ 20) comprised white-tailed deer (n=241), feral hogs (n=100), raccoons (n=34), 
and coyotes (n=22), with seroprevalence of 41.0%, 51.0%, 50.0%, and 72.7%, respectively.  
Genotyping  revealed five distinct genotypes, including the ToxoDB PCR-RFLP genotype #5 
(a.k.a type 12) for 15 isolates,  genotype #3 (a.k.a. type II) for 1 isolate, genotypes #154, #167 
and #216, each for 1 isolate. The results showed moderate to high infection rates of T. gondii in 
white-tailed deer, feral hogs, raccoons, and coyotes. Genotyping results indicated limited genetic 
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diversity with dominance of genotype #5, which has been reported as a major type in wildlife in 
North America.  
Conclusion: We conclude that T. gondii infection is common in game animals (white-tailed deer 
and feral hogs) in the southeastern US, which may pose a food safety risk to human. Further 
research is necessary to understand T. gondii transmission from wildlife to farm animals and 
humans.  
 
2. Introduction 
Toxoplasmosis, caused by Toxoplasma gondii, is zoonotic and considered a leading cause of 
human morbidity attributed to food borne illness in the United States [176]. One-third of the total 
population in the world is infected by this pathogen [1]. Women infected with T. gondii during 
pregnancy can have variable consequences including pregnancy complications, stillbirths, and 
abortions. In immunocompromised patients, such as those with AIDS, encephalitis may occur, 
which is often fatal [1]. Toxoplasmosis is one of five neglected parasitic infections, a group of 
parasitic diseases that has been targeted by the Centers for Disease Control and Prevention 
(CDC) for public health action.  Infection with T. gondii can occur by ingestion of microscopic 
oocysts in contaminated food or water, or by ingestion of tissue cysts in undercooked or raw 
meat [2], making it an important foodborne zoonotic pathogen. 
        Toxoplasma gondii infection occurs in many species of wild mammals and birds, particularly 
those that are carnivorous or ground dwelling.  Clinical toxoplasmosis occurs in a wide variety of 
US wildlife including threatened and endangered terrestrial mammals, avians, and marine 
mammals [195, 196]. Epidemiology studies in white-tailed deer populations have reported high 
seroprevalence rates (30-76%) in areas like Pennsylvania, Minnesota, Mississippi, New Jersey, 
Iowa and Ohio [177-182]. A high seroprevalence (15-84%) was also observed in raccoons from 
Iowa, New Jersey, Ohio, Kansas, Illinois, Florida, Pennsylvania, Virginia and Wisconsin [183-
185]. A high seroprevalence rate in red and gray foxes (85.9%) has also been reported in 
Kentucky, Indiana, Michigan and Ohio [178, 186]. Wild hogs from California and black bears 
from Pennsylvania also show high seroprevalence rates of 17% and 75-80% respectively [187]. 
Antibodies against T. gondii (7-17%) have also been found in wolves from remote areas in 
Alaska [188, 189]. Genotyping of isolates from wildlife suggests that wild animals maintain a 
much greater diversity of T. gondii genotypes than agricultural animals [190, 191]. There is no 
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reported association between T. gondii genotypes and disease manifestation, but some evidence 
suggests a relationship. For example, in South America where wild animal populations are more 
dominant, severe cases of human toxoplasmosis were reported even in immunocompetent adults 
[27, 28, 30, 192] and the majority of these infections were attributed to unique genotypes. Recent 
studies have reported the presence of numerous genotypes in wildlife populations in North 
America. Currently, ToxoDB PCR-RFLP genotypes #4 and #5, also known as type 12, are 
recognized as the dominant type in North America wildlife [193, 194]. It is likely that some of 
these T. gondii strains from wildlife are highly virulent, posing a potential wildlife health risk 
and a higher risk for severe toxoplasmosis if transmitted in human populations.  
     The role of wildlife in the transmission of T. gondii demands increased efforts to catalog the 
major sources of human T. gondii infection. Continued characterization is critical to 
understanding the potential risks of T. gondii to wildlife populations and its zoonotic 
implications. Seroprevalence and genotyping data from the southeast region have been 
insufficient to determine the pattern of T. gondii transmission in the area. Hence, in this study, 
we focused on determining seroprevalence and characterizing strains isolated from wildlife in the 
southeastern United States.      
 
3. Materials and Methods 
Serum with or without corresponding fresh heart or tongue tissue samples was collected from 
hunter-killed, road killed, nuisance killed (i.e. feral hogs), or research collected animals from 
multiple southeastern states (Table 5.3). Tissue samples were refrigerated until serological 
screening was completed. 
        Screening for T. gondii was performed at the clinical parasitology laboratory at the 
University of Tennessee, College of Veterinary Medicine using the Modified Agglutination Test 
(MAT) performed as previously described [152, 197] This assay is used to detect anti-T. gondii 
antibodies in blood, serum, and other bodily fluids from a wide variety of wildlife and domestic 
species.  Animals were considered Toxoplasma positive if IgG antibodies were detected at > 1:32 
dilution on MAT. Three to 5 grams of heart or tongue tissues from some seropositive hosts were 
processed and used in bioassays of mice to propagate T. gondii [5].  Isolated T. gondii strains 
were genotyped by multiplex multilocus nested PCR-RFLP (Mn-PCR-RFLP) employing 10 
genetic markers [154].  
   
 
66 
 
4. Results 
Seroprevalence of T. gondii 
A total of 471 serum/plasma samples were collected from 31 wildlife species (16 mammal and 
15 bird species) from  2011 –2014 (Table 5.1). These samples originated in six southeast states 
comprising Alabama, Georgia, Kentucky, North Carolina, South Carolina, and Tennessee (Table 
5.1). From the 471 samples, 41.6% (196/471) had MAT titers ≥ 1:32 and were considered 
positive for T. gondii infection (Table 5.2). Nine mammalian (white-tailed deer, opossum, 
raccoon, coyote, feral hog, woodchuck, elk, gray fox, and mink) and 1 bird species (rock pigeon) 
collected from five southeastern states had seropositive individuals (Table 5.1, Table 5.2). The 
mammal hosts with samples size ≥ 10 individuals comprised white-tailed deer (n=241), feral 
hogs (n=100), raccoons (n=34), coyotes (n=22), opossum (n=12), and gray squirrels (n=14) with 
seroprevalence of 41%, 51%, 50%, 73%, 50%, and 0% respectively.   
     In Tennessee, 309 serum samples from 29 animal species were collected from 10 
counties/sites and tested (Table 5.1). Overall, 37.5% (116/309) were positive for T. gondii 
infection. A total of 167 white-tailed deer samples were collected from various counties 
including Loudon, Fayette (Ames plantation), Anderson (Oakridge National Laboratories) and 
Coffee (Arnold Engineering Development Complex) area; 39.5% (66/167) were positive. Thirty-
four raccoon samples were collected from Knox, Fayette, and Kingston counties, 50% (17/34) 
were positive. Of the 27 feral hog serum samples collected from the Tennessee side of Great 
Smoky Mountains National Park (GSMNP), 40.7% (11/27) were positive. From 17 coyote 
samples collected in Fayette County, 11 (64.7%) were positive. Additionally, 50% (6/12) of 
opossum from Knox and Fayette counties were positive. Overall, the results from Tennessee 
indicate T. gondii infection is common in wildlife (Table 5.1).  
     In North Carolina, 74 serum samples (73 from feral hogs, 1 from a black bear) were collected  
from the GSMNP (Table 5.1), 54.1% (40/74) were positive. For the feral hogs, 54.8% (40/73) 
were positive to T. gondii infection.  In South Carolina, 74 serum samples from white-tailed deer 
in Laurens County were tested and 44.5% (33/74) were seropositive. In Georgia, 6 serum 
samples were collected from 5 coyotes and 1 gray fox in Jefferson and Putnam counties (Table 
5.1). The 5 samples from coyotes in Putnam County were all seropositive.  The 1 sample from 
the gray fox in Jefferson County tested seronegative. Four serum samples from 4 animal species  
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Table 5.1:  Seroprevalence rates of T. gondii categorized by State and County. 
 
State of 
Origin 
County/Site  
Species  
Seropositive/ 
total 
Seroprevalence 
(County) 
Seroprevalence 
(State) 
Tennessee 
Loudon 
white tailed 
deer 
5/9 55.6% 
37.5% (116/309) 
Knox 
Virginia 
opossum 
1/2 
22.4% (13/58) 
woodchuck 1/4 
mink 1/1 
raccoon 5/12 
gray fox 2/3 
opossum 2/3 
pigeon 1/1 
22 other 
wildlife 
species* 0/32 
Coffee 
white tailed 
deer 
1/3 
8.3% (1/12) 
gray squirrel 0/9 
Ames Plant 
coyote 11/17 
54.1% (59/109) 
white tailed 
deer 
40/77 
raccoon 5/8 
opossum 3/7 
GSMNP 
black bear 0/1 
39.2% (11/28) feral hog 11/25 
GSMP feral hog 0/2 
Kingston raccoon 7/13 53.8% 
Oak Ridge 
white tailed 
deer 
18/64 28.1% 
AEDC, 
Decherd 
white tailed 
deer 
2/14 14.2% 
Jefferson raccoon 0/1 0% 
Roane mink 0/1 0% 
South 
Carolina 
Laurens 
white tailed 
deer 
33/74 44.5% 44.5% 
North 
Carolina 
Cataloochee feral hog 0/2 0% 
54% (40/74) 
GSMNP 
feral hog 40/71 
55.5% 
black bear 0/1 
Georgia 
Jefferson gray fox 0/1 0% 
83.3% (5/6) Putnam coyote 5/5 100% 
Brent  woodchuck 0/1 0% 
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Overall positive rate = 196/471 (41.6%) 
 GSMP= Great Smoky mountain Parkway, GSMNP=Great Smoky mountain National Park, 
AEDC= Arnold Engineering development complex 
*One samples from each of the following wildlife: American Crow, American robin, Beaver, 
Belted Kingfisher, Chickadee, Chimney Swift, Chipmunk, Eastern Chipmunk, Fox squirrel, Gray 
Catbird, Hermit Thrush, House Sparrow, Oven Bird, Pileated Woodpecker, Rock Pigeon, Tufted 
Titmice, Turkey Vulture. 
Two samples from: Blue Jay and Mourning Dove. 
Three samples from: Cotton-tailed Rabbit 
Four samples from: Eastern Cottontail and gray squirrel 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.1 (continued) 
State of 
Origin 
County/Site  
Species  
Seropositive/ 
total 
Seroprevalence 
(County) 
Seroprevalence 
(State) 
Alabama Hale 
eastern 
cottontail 
0/1 
0% 0% (0/3) armadillo 0/1 
gray 
squirrel 
0/1 
Kentucky 
Perry elk 2/3 66.6% 
50% (2/4) 
Knott elk 0/1 0% 
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Table 5.2: Seroprevalence rate of T. gondii categorized by species. 
 
  Host No. of 
samples 
MAT titers Sero-prevalence% 
  
<
1
:3
2
 
1
:3
2
 –
 
1
:1
2
8
 
1
:2
5
6
-
1
:1
0
2
4
 
1
:2
0
4
8
 –
 
1
:8
1
9
2
 
>
1
:8
1
9
2
  
Mammals 
White tailed deer 241 142 59 11 11 18 41.0 
Feral hog 100 49 33 13 4 1 51.0 
Raccoon 34 17 6 7 0 4 50.0 
Coyote 22 6 5 4 4 3 72.7 
Opossum 10 5 2 2 1 0 50.0 
Woodchuck 5 4 1 0 0 0 20.0 
Elk 4 2 1 1 0 0 50.0 
Gray fox 4 2 2 0 0 0 50.0 
Mink 2 1 0 0 1 0 50.0 
Virginia Opossum 2 1 1 0 0 0 50.0 
Gray squirrel 14 14 0 0 0 0 0.0 
Eastern cottontail 5 5 0 0 0 0 0.0 
Cotton-tailed rabbit 3 3 0 0 0 0 0.0 
Black bear 2 2 0 0 0 0 0.0 
Armadillo 1 1 0 0 0 0 0.0 
Beaver 1 1 0 0 0 0 0.0 
Chipmunk 1 1 0 0 0 0 0.0 
Eastern chipmunk 1 1 0 0 0 0 0.0 
Fox squirrel 1 1 0 0 0 0 0.0 
Birds 
Pigeon 1 0 1 0 0 0 100.0 
Blue jay 2 2 0 0 0 0 0.0 
Mourning dove 2 2 0 0 0 0 0.0 
American crow 1 1 0 0 0 0 0.0 
American robin 1 1 0 0 0 0 0.0 
Belted kingfisher 1 1 0 0 0 0 0.0 
Chickadee 1 1 0 0 0 0 0.0 
Chimney Swift 1 1 0 0 0 0 0.0 
Gray Catbird 1 1 0 0 0 0 0.0 
Hermit thrush 1 1 0 0 0 0 0.0 
House sparrow 1 1 0 0 0 0 0.0 
Oven bird 1 1 0 0 0 0 0.0 
Pileated woodpecker 1 1 0 0 0 0 0.0 
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Table 5.2 (continued)    
Host No. of 
samples 
MAT titers Sero-
prevalence% 
  
<
1
:3
2
 
1
:3
2
 –
 
1
:1
2
8
 
1
:2
5
6
-
1
:1
0
2
4
 
1
:2
0
4
8
 –
 
1
:8
1
9
2
 
>
1
:8
1
9
2
  
Rock pigeon 1 1 0 0 0 0 0.0 
Tufted Titmice 1 1 0 0 0 0 0.0 
Turkey Vulture 1 1 0 0 0 0 0.0 
Total 471 275 111 38 21 26 
41.6% 
(196/471) 
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in Alabama were all negative (Table 5.1). Two of 4 samples from elk in Kentucky were positive 
(50%).  
 
Isolation and genotyping of T. gondii strains 
The tissue samples (hearts and tongues) from 66 seropositive wildlife bioassayed in mice are 
listed in Table 5.3. These samples comprised: 33 from white-tailed deer, 11 from feral hogs, 8 
from raccoons, 8 from coyotes, 2 from elk, 2 from opossums, 1 from mink and 1 from gray fox. 
Nineteen T. gondii isolates were obtained by bioassay (13 white-tailed deer, 3 feral hogs, 2 
coyotes and 1 mink). All samples were genotyped by the 10 PCR-RFLP markers and the results 
are summarized in Table 5.4. Five distinct genotypes were identified: ToxoDB PCR-RFLP 
genotype #5 (15 isolates), #3 (1 isolate), #154 (1 isolate), #167 (1 isolate) and #216 (1 isolate). 
Of the 13 isolates obtained from white-tailed deer, 9 were from South Carolina and 4 from 
Tennessee.   
 
5. Discussion 
The present study demonstrates that T. gondii infection is widespread in wild mammals from the 
southeastern United States. We collected sera from 471 wild animals, including 453 mammals 
and 18 birds between 2011 and 2014.  Overall, 41.6% were positive for T. gondii infection, 
however, only one of the 18 birds was seropositive, whereas mammal hosts with samples size ≥ 
10 individuals all had high prevalence >40%. Type 12 (a. k. a. Toxo DB #5) is the most common 
circulating genotype in wildlife in this region of the US, which is in agreement with previous 
studies reporting the prevalence of type 12 genotype in white-tailed deer populations [36, 193]. 
Genotypes #156 and #167 have been previously reported from goats in the USA [199]. Two 
isolates from coyote (TgWtdTn 122 and 142) and 1 mink isolate (TgMnkTn17) obtained from 
Tennessee, belong to genotype #5 and #3 respectively. Genotype #3 belongs to type II clonal 
lineage of T. gondii which is the most dominant lineage distributed globally. Furthermore, the 2 
feral hog isolates (TgHogNc 194 and 227) from North Carolina also belonged to genotype #5, 
which is commonly distributed in North America [193].  
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Table 5.3:  Results for bioassay in mice for T. gondii. 
 
Sampl
e ID Host 
Loc
a-
tion 
Date  
Sample 
collected 
MAT 
titre 
Days 
between 
collection 
and 
inoculation 
Mice 
bioassaye
d Isolate ID 
13 Elk KY 10/8/2011 128 6 2 Nd 
14 Elk KY 10/8/2011 512 6 3 Nd 
16 WTD TN 9/19/2011 128 6 2 Nd 
17 Mink TN 10/8/2011 >8192 6 3 TgMnkTn17 
37 WTD SC 10/15/2011 ≥8192 16  2 Nd 
40 WTD SC 10/15/2011 ≥8192 16  3 TgWtdSc40 
43 WTD SC 10/15/2011 ≥8192 16  3 TgWtdSc43 
60 WTD SC 10/15/2011 ≥8192 16  3 TgWtdSc60 
77 Gray fox TN 10/17/2011 32 14  3 Nd 
78 WTD SC 11/13/2011 ≥8192 9  2 TgWtdSc78 
79 WTD SC 11/13/2011 2048 9  2 Nd 
80 WTD SC 11/13/2011 2048 9  2 Nd 
88 WTD SC 11/13/2011 ≥8192 9  2 TgWtdSc88 
95 WTD SC 11/13/2011 2048 9  2 Nd 
98 WTD SC 11/13/2011 2048 9  2 TgWtdSc98 
99 WTD SC 11/13/2011 2048 9  2 TgWtdSc99 
102 WTD SC 11/13/2011 ≥8192 9  2 Nd 
110 WTD SC 11/13/2011 ≥8192 9  2 TgWtdSc110 
113 WTD SC 11/13/2011 ≥8192 9  2 TgWtdSc113 
119 Raccoon TN 1/21/2012 2048 12  2 Nd 
121 Raccoon TN 1/21/2012 2048 12  1 Nd 
122 Coyote TN 1/21/2012 512 12  1 TgCyTn122 
124 Raccoon TN 1/21/2012 2048 12  2 Nd 
126 Coyote TN 1/21/2012 ≥8192 12  2 Nd 
133 Raccoon TN 1/27/2012 ≥8192 20  2 Nd 
136 Opossum  TN 2/2/2012 512 14  2 Nd 
138 Opossum  TN 2/2/2012 512 14  2 Nd 
142 Coyote TN 2/2/2012 4096 14  2 TgCyTn142 
151 Coyote GA 3/28/2012 ≥8192 6  3 Nd 
152 Coyote GA 3/28/2012 4096 6  3 Nd 
173 Raccoon TN 6/13/2012 128 5  3 Nd 
174 Raccoon TN 6/13/2012 2048 5  3 Nd 
176 Raccoon TN 6/13/2012 2048 5  3 Nd 
194 FH NC 1/28/2013 4096 16  3 TgHogNc194 
   
 
73 
 
        
        
Sampl
e ID Host 
Loc
a-
tion 
Date  
Sample 
collected 
MAT 
titre 
Days 
between 
collection 
and 
inoculation 
Mice 
bioassaye
d Isolate ID 
 
195 FH NC 1/28/2013 128 16  2 Nd 
197 FH NC 1/31/2013 128 16  2 Nd 
201 FH NC 2/8/2013 512 20  2 Nd 
210 Raccoon TN 1/17/2013 2048 42  2 Nd 
211 Coyote TN 1/22/2013 2048 37  3 Nd 
212 Coyote TN 1/22/2013 ≥8192 35  2 Nd 
215 Coyote TN 1/24/2013 2048 35  2 Nd 
227 FH NC 4/9/2013 128 16  3 TgHogNc227 
300 WTD TN 11/10/2013 32 10  2 Nd 
313 WTD TN 11/10/2013 128 10  2 Nd 
323 WTD TN 11/10/2013 32 10  2 Nd 
334 WTD TN 11/12/2013 128 8  2 Nd 
335 WTD TN 11/12/2013 128 9  2 TgWtdTn335 
345 WTD TN 11/12/2013 128 8  2 Nd 
352 WTD TN 11/12/2013 128 8  2 Nd 
354 WTD TN 11/12/2013 128 8  2 Nd 
355 WTD TN 11/12/2013 128 8  2 Nd 
372 WTD TN 12/9/2013 ≥8192 4  2 TgWtdTn372 
373 WTD TN 12/9/2013 512 4  2 Nd 
383 WTD TN 12/9/2013 512 4  2 Nd 
385 WTD TN 12/9/2013 512 4  2 Nd 
387 WTD TN 12/9/2013 ≥8192 4  2 TgWtdTn387 
389 WTD TN 12/9/2013 2048 4  2 Nd 
399 WTD TN 12/15/2013 2048 8  2 TgWtdTn399 
400 WTD TN 12/15/2013 128 8  2 Nd 
402 WTD TN 12/15/2013 128 8  2 Nd 
452 FH NC 1/16/2014 128 18  3 TgHogNc452 
458 FH NC 1/24/2014 1024 10  3 Nd 
462 FH NC 1/31/2014 128 20  3 Nd 
466 FH NC 2/6/2014 128 14  3 Nd 
480 FH NC 2/12/2014 128 8  3 Nd 
WTD=white tailed deer, FH=feral hog. 
SC=South Carolina, NC=North Carolina, TN=Tennessee, GA= Georgia, KY=Kentucky
Table 5.3 (continued) 
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ID Host Location SAG1 5’-3’ 
SAG2 
alt. 
SAG2 
SAG3 BTUB GRA6 c22 
-8 
c29 
-2  
L358  PK1 Apico Genotype  
TgWtdSc40 WTD SC u-1 II II II II II II II I II I #5 
TgWtdSc43 WTD SC u-1 II II II II II II II I II I #5 
TgWtdSc60 WTD SC u-1 II II II II II II II I II I #5 
TgWtdSc78 WTD SC u-1 II II II II II II II I II I #5 
TgWtdSc99 WTD SC u-1 II II II II II II II I II I #5 
TgWtdSc113 WTD SC u-1 II II II II II II II I II I #5 
TgWtdSc88 WTD SC I II II III II II II u-1 III II I #154 
TgWtdSc98 WTD SC II or 
III 
I I I I I I III III III III #167 
TgWtdSc110 WTD SC I I I III III I III III III I III #216 
               
TgHogNc194 FH NC u-1 II II II II II II nd I nd nd #5 
TgHogNc227 FH NC u-1 II II II II II II nd I nd nd #5 
TgHogNc452 FH NC u-1 II II II II II II II I II I #5 
               
TgMnkTn17 Mink 
TN 
II or 
III 
II II II II II II II II II I #3 
TgCyTn122 Coyote TN u-1 II II II II II II II I II I #5 
TgCyTn142 Coyote TN u-1 II II II II II II II I II I #5 
TgWtdTn335 WTD TN u-1 II II II II II II II I II I #5 
TgWtdTn372 WTD TN u-1 II II II II II II II I II I #5 
TgWtdTn387 WTD TN u-1 II II II II II II II I II I #5 
TgWtdTn399 WTD TN u-1 II II II II II II II I II I #5 
Table 5.4 Genotyping data for T. gondii isolates from wildlife. 
WTD=white tailed deer, FH=feral hog. 
SC=South Carolina, NC=North Carolina, TN=Tennessee 
nd = no data. 
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6. Conclusion 
In addition to the commonly observed genotypes, we also isolated several non-clonal types 
circulating in sampled populations. This is of interest, as previous epidemiological studies have 
reported a link between the prevalence of non-clonal genotypes and cases of congenital ocular 
and severe disseminated toxoplasmosis in the area such Brazil [3]. White-tailed deer is one of the 
most dominant wildlife species found in North America as well as venison is a common game 
meat. Thus, the high seroprevalence in this species indicates that deer could serve as an 
important source of human infection. Hence, people consuming wild venison should be advised 
to cook the meat properly and use proper caution while handling the raw meat. Future 
genotyping and seroprevalence studies in wildlife hosts and their role in the transmission cycle 
will increase the understanding of risks associated with T. gondii in human populations.  
 
7. Future perspectives 
In this study, we measured the seroprevalence rate among wildlife from six southeastern United 
States; including Tennessee, Georgia, North Carolina, South Carolina, Kentucky, and Alabama 
and observed a high seroprevalence rate among the animals consumed by humans as game meat. 
Even though the seroprevalence studies are rising, some areas remain underrepresented and may 
prove as a risk to humans in the close vicinity. Thus, in future, more seroprevalence studies need 
to be attempted, especially among wildlife, as consumption of game meat is a common practice. 
Additionally, previous studies have shown that isolates circulating among wildlife may cause 
severe cases of toxoplasmosis in humans. Thus, expansion of the existing knowledge regarding 
strains of T. gondii infecting wildlife is of importance and should be a part of future goals.  
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CONCLUSIONS 
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Toxoplasma is one of the pathogens included in the category of the neglected parasitic infections, 
a group of parasitic diseases that has been targeted by the Centers for Disease Control and 
Prevention (CDC) for public health action. This disease can be spread by contaminated food and 
water sources as well as can be vertically transmitted. Furthermore, Toxoplasma has the capacity 
to remain infectious in humans as well as almost all warm-blooded animals and can reactivate 
under immunocompromised conditions causing a severe form of infection and in some cases 
death. This asserts the importance of studying the transmission pattern, seroprevalence rates as 
well as the genes that play a role in the maintenance of infection.  
        At present, the studies to understand the virulence of the parasite Toxoplasma have been 
carried out using the mouse as the model organism. However, the methodology used between 
labs varies considerably, making it difficult to compare results between different labs. Thus, it is 
essential to establish a standard method in order to make results comparable and create a 
database for future studies. Hence, in Chapter 1 we focused on discussing the different factors 
that may lead to variability in results; including the route of infection, life stage of the parasite, 
and the number of passages of the parasite in mice or cell culture, and the mouse host lines. 
Further, we put forth a protocol to facilitate the integration of T. gondii virulence data throughout 
the research community.  
        Recent studies using PCR-RFLP technique have established that the population and 
diversity structure of Toxoplasma is complex. This study also showed that T. gondii is spread 
globally, however; the dominance of certain lineages varies geographically. Type II even though 
spread globally, was found to be most dominant in Europe compared to other regions; including 
Africa, North and South America. Additionally, cases of congenital toxoplasmosis infected with 
type II T. gondii were reported from the European continent. Thus, it is of interest to study the 
transmission pattern and origin of this dominant lineage. Our study (Chapter 2) based on 299 
type II isolates collected globally revealed that diversity of type II lineage is most in Europe and 
Africa than any other continent. Furthermore, isolates from Europe and Africa were found to be 
older based on the phylogenetic tree. Taken together, in this study we identified that the type II 
lineage may have originated in the Old World comprise of Europe and Africa and have 
transmitted to the New World of America from the Old World.          
        Similar to type II lineage, type III lineage was found out to be the second most common 
lineages among all others. Unlike type II, type III is found in higher numbers in South America. 
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It is therefore, interesting to investigate whether type III MRCA originated in South America, or 
if it is transmitted and recently expanded in this region. Results of our study (Chapter 3) showed 
that type III strains may have originated in the New World near Central America and are being 
transmitted back to the Old World (Europe and Africa) from the New World (America). 
Additionally, type III strains from North America were not clustered together when compared to 
type II lineages from this region. This together suggests that type III lineage may have originated 
in the New World and transmitted to North America independently during multiple events in the 
history.  
        Toxoplasma gondii is capable of infecting almost all warm-blooded animals [1]. As T. 
gondii can be transmitted to humans via consumption of contaminated meat, the study of the 
seroprevalence rate among the wildlife is of importance [2]. Furthermore, severe cases of 
toxoplasmosis have been reported to be infected with the strains found to be circulating among 
wildlife areas [27, 28, 30]. Hunting is a common practice in the southern region of US, however; 
the seroprevalence and genotyping reports of Toxoplasma are limited in this area. In Chapter 4 
we focused on reporting the seroprevalence rate and genotyping of strains among the wildlife of 
six regions of Tennessee, Georgia, North Carolina, South Carolina, Kentucky, and Georgia. Our 
study on a collection of 471 wildlife sera samples showed high seroprevalence rate among game 
meat animals including white-tailed deer. Furthermore, one previously unidentified genotype and 
other atypical genotypes were found to be circulating among the wildlife belonging to these 
regions.  
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APPENDIX A: MODERN DAY T. GONDII GENETIC DIVERSITY IS DERIVED FROM 
RECOMBINATION OF FIVE ANCESTRAL GENOMES 
 
1. Introduction 
 T. gondii is one of the most widespread pathogens and is responsible for causing disease across 
the globe [1]. The most recent knowledge on the diversity structure of T. gondii indicates that 
population structure is much more complex than the previous notion of three clonal lineages 
[11]. The accumulation of information from genotyping studies has also revealed previously 
unknown genotypes of T. gondii. Previous study with 46 T. gondii samples has shown that the 
mixing of four ancestral groups can define the population structure of T. gondii [221]. However, 
this study was based on limited T. gondii strains, which may miss important ancestors. Thus, to 
better understand the composition of current population structure and to correctly identify the 
number of ancestral genomes, we utilized sequence data for 160 strains collected worldwide. Our 
study is an update on the previous studies utilizing few strains representing the population of T. 
gondii.   
 
2. Materials and Methods 
 
DNA sequencing  
DNA sequencing was performed by our collaborators in China. A hundred and sixty DNA 
samples were collected from previous studies in our laboratory [36]. Location and host 
information for these isolates were obtained from previously published papers (Table A.1). DNA 
for all the isolates was either obtained from the heart or brain tissues of experimentally infected 
mice or cell culture.  Fifty genetic loci across the 65 Mb T. gondii genome were pre-amplified by 
multiplex PCR in three different groups.  
 
SNP identification and STRUCTURE analysis 
Sequence data available for 47 loci for a total of 160 strains of T. gondii was aligned and SNPs 
was identified using Molecular Evolutionary Genetics Analysis (MEGA) software v 6.0.  The 
number of population clusters (k) were predicted individually for each marker as well as for 
concatenated data for all SNPs,  using STRUCTURE v2.3.4 ADMIXTURE  and Linkage model 
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respectively, with ancestral clusters set from K=1 to 10 (Table A.1). The results are averages 
across three independent simulations with 103 burn-in iterations, followed by 103 MCMC 
iterations.  
 
Chromosome painting 
Based on the population clusters identified for 37 loci using STRUCTURE v2.3.4, a chromosome 
map was constructed using Microsoft Excel (2010). 
 
Phylogenetic analysis 
A neighbor joining tree was also constructed using sequence data of 43 loci for 160 (type I, II and 
III) strains of T. gondii using SplitsTree 4.8 [167] 
 
3. Results 
To reveal the shared ancestry among isolates, local admixture analysis was conducted on SNPs 
identified for 37 loci located on 14 different chromosomes for a total of 160 strains (Figure A.1). 
Each strain was assigned a particular ancestral population based on admixture analysis and was 
represented by a colored block. A chromosome painting map was constructed for the identified 
population clusters for all 37 loci of 160 strains. The color block patterns were compared 
horizontally among different populations to reveal the shared ancestry across 160 strains of T. 
gondii (Figure A.1 ). When strains were aligned by clades identified using sequence data for 160 
strains of T. gondii (Attachment 1), recombination was observed for the population as a whole. 
Divison of haploblocks being shared across strains of specific lineages was not observed (Figure 
A.1). 
        Although chromosome painting revealed the recombination events among the current 
population, it failed to report the admixture pattern for the population as a whole. Thus, to 
illustrate this more directly, STRUCTURE analysis was conducted for SNPs across all the 160 
strains, using Linkage model (Figure A.2). This analysis revealed that the population is derived 
from five ancestral genomes similar to strains; type I (BOF, GPHT, etc.), type II (PTG, DEG 
etc.),  type III (P89, TgCatBr3 etc.), MAS and TgCkGh1. Additionally, the modern day type I 
appeared to be a result of inheritance of haploblock from the ancestral PTG (type II) and BOF or 
GPHT (ancestral type I) strains (Figure A.2a). Whereas, the modern day type III strains was a 
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result of a cross between ancestral PTG (type II) and P89 (ancestral type III) strains. These 
findings were in agreement with a 2006 study [220]. Similar to the results from chromosome 
painting, irrespective of the region, the population showed recombination (Figure A.2b). As 
expected, the majority of isolates from North America (TgWtdUs8, TgSoUs1, TgShUs32 etc.) 
showed genetic makeup similar to type II reference PTG strain (Figure A.2b). South America 
population as a whole showed a lot of recombination and could be virtually divided into three 
major clusters. A third of the population had the genetic makeup similar to GT1 (type I) strain, 
one-third similar to MAS (atypical) and one-third similar to CTG (type III) (Figure A.2b).  
 
4. Conclusions 
The mosaic genomic patterns based on chromosome painting shows ongoing recombination in 
the current population where large chromosomal haploblock are shared among members of 
different clades (Figure A.1). Remarkably, our findings based on genome–wide polymorphic 
data of 160 strains of T. gondii is in strong agreement with the previous reports [220, 221]. Our 
data suggests that the current population (based on the assortment of 160 strains) is inherited 
from five ancestral population clusters (Figure A.2a). Furthermore, based on our data the 
proposed genealogy of three modern day reference strains representing the major clonal lineages 
(GT1, PTG, and CTG) is in accordance with previous reports. The distribution of the colored 
haploblock strongly suggests that a cross between type II (PTG/green) and type III (P89, 
TgCatBr3 etc./blue) strain gave rise to modern day type III lineage represented by CTG (Figure 
A.2a). The P89 population was previously referred as β strain in a 2006 study (Boyle et al. 
2006). Similarly, modern day type I strain (GT1) is a result of a cross between type II 
(PTG/green) and type I (BOF, GPHT, FOU etc. /red) strain, hypothetically referred as α strain in 
a previous study [221]. Genome–wide SNPs STRUCTURE analysis for 160 strains, revealed that 
the current population structure is a mixture of five ancestral groups. The number of ancestral 
groups (five) suggested through our analysis is close to previously reported four ancestral  
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Figure A.1: Chromosome painting of 160 T. gondii strains. 
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Figure A.2: Analysis of present day T. gondii population structure using genome-wide 
SNPs data for 160 strains using STRUCTURE. 
 
FigureA.2a: Grouped by ancestor. 
Figure A.2b: Grouped by geographical region. 
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Figure A.2 (continued) 
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 Figure A.2 (continued) 
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groups, however, this 2007 study was based on intron sequences of a limited number of T. gondii 
strains (n=46) [220]. 
Based on the genome-wide SNPs analysis, South American strains also showed the dominance 
of strains with haploblock similar to type I and atypical strains. This observation also reflects on 
the severity of disease due to infection with T. gondii in South America. AIDS patients are often 
found to be infected with type I strain and atypical strains are often associated with the severe 
forms of diseases. Together, this study suggests that the current day population structure of T. 
gondii is a result of recombination of five ancestral groups. 
 
5. Future perspectives 
Even though limited variability exists among different lineages of T. gondii, studies have 
reported that certain genotypes are associated with severe forms of toxoplasmosis. Our study has 
shown that strains from South America show similar haploblock pattern to type I like and 
atypical strains, often associated with extreme cases of toxoplasmosis. Thus, in future, it will be 
interesting to study the oral infectivity and transmissibility of representative strains from this 
study. This will aid in exposing the admixture of lineages best adapted to domestic transmission. 
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APPENDIX B: TO ESTABLISH AN EXPERIMENTAL PROTOCOL TO STUDY 
PHASE INTERCONVERSION IN TOXOPLASMA GONDII 
 
1. Introduction 
The apicomplexan life cycle requires switching between distinct developmental stages. The life 
cycle of T. gondii can be divided into three different stages: tachyzoite, bradyzoite and 
sporozoite [1]. Tachyzoites represent the rapidly dividing stage whereas; bradyzoites are the 
slow replicating form of the parasite responsible for chronic infection in the host. Following 
infection, T. gondii enters into a rapidly dividing tachyzoite form that enters the lymph nodes and 
can disseminate by infecting migratory cells like dendritic cells and macrophages. Eventually, on 
encountering the host immune system stress responses, the tachyzoite form is converted to a 
more slowly replicating dormant bradyzoite form. Bradyzoites enclosed in the cyst walls are 
resistant to immune responses and can be retained primarily in brain and muscle neurons for the 
entire lifespan of the infected host [1, 8]. Infections in immunocompetent individuals are mostly 
asymptomatic. However, the key to T. gondii pathogenesis is its ability to differentiate from a 
rapidly- replicating tachyzoites stage during acute infection to a relatively non-immunogenic, 
dormant bradyzoite stage contained in tissue cysts [211]. Although tissue cysts are considered 
dormant, they occasionally rupture and release bradyzoites that convert to faster-replicating 
tachyzoites which in turn disseminate and can cause severe pathology and death in the absence 
IFN-γ-dependent cell-mediated immune response [211-213]. Reactivation is thus a serious and 
life-threatening condition in immune-compromised individuals. Bradyzoite formation is also of 
concern during organ transplantation between individuals. The combination of drugs like 
sulfonamide and pyrimethamine can readily inhibit tachyzoites; however, no drug currently 
exists that inhibits the parasite in the bradyzoite form. Since tachyzoite to bradyzoite conversion 
is the key to the establishment of a chronic infection and the reverse phenomenon is responsible 
for life-threatening pathology, understanding of the molecular prerequisites for interconversion 
will aid in developing a strategy to coerce the parasite out from latency and treat it using existing 
drugs [93, 114, 116, 214]. In order to achieve this overarching aim, the goal of the study was to 
establish a methodology to successfully convert the tachyzoite form into a bradyzoite form and 
vice versa, in vitro using external stress factors.  
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Specific Aims 
2.1 To establish a protocol to study stress induced tachyzoite to bradyzoite conversion. 
Previous studies have shown that tachyzoite to bradyzoite differentiation can be induced in vitro 
in response to physiologically relevant exogenous stress like a NO donor (sodium nitroprusside).  
Infected human foreskin fibroblast (HFF) cells will be cultured in medium containing sodium 
nitroprusside (SNP) for three to four days at 37°C. Exposure of parasites to SNP will be used to 
enhance bradyzoite differentiation in vitro [114, 116]. 
 
2.2 Time course expression analysis using RNA-seq. 
Time course expression profiles will be carried out on the stress induced tachyzoites using RNA-
seq. RNA-seq technology should reveal a snapshot of RNA presence and quantity from a 
genome at a given moment in time[215].  
 
2.3 Analysis of the profile using GeneNet Package. 
GeneNet package will be used to analyze time-series data obtained from RNA-seq to identify the 
genes that are upregulated/downregulated [216, 217] (Figure B.1). 
 
2.4 Gene knockout studies to confirm the role of the predicted gene. 
Gene deletion assay will be performed for the predicted gene to confirm its role in regulating the 
tachyzoite to bradyzoite conversion. 
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Figure B.1: Examples of network structure of predicted genes analyzed using Gene 
net analysis [216]. 
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2. Materials and Methods 
 
Parasites 
The ME49 strain originally isolated from the diaphragm of sheep was selected for this study. The 
parasites were cultured in human foreskin fibroblast (HFF) cells grown in Dulbecco’s modified 
Eagle medium containing 10% fetal bovine serum (FBS), 10 mM HEPES (pH 7.4), 1 mM 
glutamine without antibiotics at 37°C under 5% CO2. 
 
In vitro differentiation of T. gondii 
In vitro bradyzoite differentiation was achieved using exogenous NO donor (sodium 
nitroprusside). A three-day confluent monolayer of HFF cells grown in 6-well plates was infected 
with tachyzoites of ME49 strain.  Differentiation was induced by adding 70 μM SNP in 
Dulbecco’s modified Eagle medium containing 10% fetal bovine serum (FBS), 10 mM HEPES 
(pH 7.4), 1 mM glutamine without antibiotics. Cultures were incubated for 2 to 7 days with 
medium changed daily. HFF cells infected with ME49 and cultured in medium without SNP were 
used as a control for the study. 
 
Immunostaining 
HFF cells grown on chamber slides (Labtek, Campbell, CA) were infected with ME49 parasites 
and monitored daily after infection. For immunostaining, cells were washed with PBS three 
times and fixed using 4% formaldehyde for 30 minutes. Cells were permeabilized using 0.5% 
Triton X-100 diluted in PBS for 20 min at RT and blocked in blocking buffer (0.1% Triton X-
100, 10% BSA diluted in PBS) for 1 hour at 37℃. Cells were incubated in primary antibody, 
Rabbit anti-Bag1 antibody (1:100) overnight at 4℃.The cells were washed gently with PBS, and 
the secondary antibody, Goat-anti-rabbit IgG-FITC (Sigma-Aldrich )(1:80 dilution) was added to 
each well and incubated at 37℃ for 1 hour. The cells were washed gently with PBS 3 times. 
Coverslips were removed from each well air-dried and mounted using VECTASHIELD anti-
fading mounting medium with DAPI (Vector laboratories, Burlingame, CA). 
Immunofluorescence was observed under a confocal microscope. 
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Detection of Bag1 using Western blot 
HFF cells cultured in 6 well plates were infected with ME49 and allowed to invade for 24 hours 
or 4-6 parasites per vacuole stage. Medium (with or without SNP) was changed daily for both the 
control and experimental sample. Respective 6 well plates were processed for the western blot. 
Cells on these 6 well plates were harvested using a scraper and transferred to Eppendorf tubes. 
Cells were lysed using a RIPA buffer containing 1% phosphatase inhibitor (Roche), and 1% 
protease inhibitor (Roche). Protein concentrations were measured using the BCA method. 20 μg 
of total protein for day 2 control, day 3 control,  drug- treated day 2 –day 5 and revert day 1 and 
2 was used for SDS-PAGE. Proteins in the gel were transferred to a LiCor Immobilon-FL PVDF 
membrane and allowed to dry overnight.  The next day the membranes were sliced into two parts 
at 32 kDa and blocked in LiCor blocking buffer for 1 hour at 37°C. The upper part was incubated 
with anti-β-tubulin (1:2500) (Dr.Sibley lab) and the bottom part was incubated with anti-Bag1 
(1:2500) at 37°C for 1 hour. The membranes were washed with TBST 4x5 times. Membranes 
were incubated with the secondary IR dye Goat anti-rabbit antibody at a 1:10000 dilution for 1 
hour at room temperature followed by washing with TBST 4x5 and visualized using LiCor 
Odyssey instrument. 
 
3. Results 
Previously studies have shown that exogenous stress can successfully induce differentiation of 
tachyzoites in vitro. Sodium nitroprusside a NO donor has been reported as the most 
physiologically relevant stress and therefore chosen as the stress factor for this study. Studies 
have reported that ME49 strain of T. gondii is efficient in the formation of cysts in vitro. To 
induce the conversion of tachyzoite to bradyzoite, 70 uM concentration of SNP was used for our 
study. In order to confirm the interconversion process in vitro, Immunostaining and western 
blotting were performed.  
 
In vitro cyst development 
Fluorescent intensity of bradyzoite stage specific protein Bag1 was used as a marker for the stage 
conversion [218]. Cysts were stained with anti-Bag antibody and observed by confocal 
microscopy. Representative examples of staining with Bag1 and DAPI for each day are shown in 
the figure below (Figure B.2 a-d). The intensity of Bag1 increased from day 2 to day 4 post drug 
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treatments. For the control, Bag1 intensity increases slightly in comparison to the drug treated 
parasites and lysed at day 2 post infection. These results reveal that SNP drug treatment can 
successfully retain the parasites as cysts in vitro. Additionally, on removing the stress, the 
intensity of Bag1 fluorescence decreased till day 2 post stress removal and is lysed at Day 2 
(Figure B.2 a-d). Together, these results show that the ME49 strain of T. gondii is converted to 
cyst form in vitro using a NO donor and successfully reverts back to tachyzoite form on the 
release of the exogenous stress.  
 
Western Blot 
To confirm the differentiation of tachyzoite to bradyzoite, Bag1 protein expression was 
quantified using western blot (Figure B.3). Western blot analysis showed that Bag1 protein 
expression increased from day 2 to day 5 for SNP treated plates. Whereas, the Bag1 protein was 
absent for day 2 and day 3 control post infection. This confirms that in vitro, tachyzoites are 
converted to bradyzoites post treatment with SNP. Interestingly, Bag1 protein expression appears 
to be more at revert day 1 and 2 (SNP stress removed). This could be explained by the possibility 
that Bag 1 protein is not immediately degraded on reversion to the tachyzoite form. However, 
bradyzoites are confirmed to be reverted to tachyzoite form as the PV is lysed, following parasite 
release on day 2 post stress removal. 
 
4. Conclusion 
So far we have successfully established a protocol to study the interconversion dynamics of T. 
gondii. These results are in agreement with previous studies reporting the use of SNP as the 
exogenous NO donor for conversion of tachyzoites to bradyzoites in vitro. Additionally, our 
study also shows that on removing the external stress factor (in this study SNP), bradyzoites can 
be converted back to tachyzoites form. However, this conversion seems to be really fast. Hence, 
the time points used for the RNA profile in future should be decided accordingly.  
 
5. Future perspectives 
The above established protocol can be used to study the most important/ master regulatory 
gene(s) involved in the conversion of tachyzoites into bradyzoite stage and vice versa for T.  
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Figure B.2 (a-d): Expression of Bag1 (Green) antigen following the in vitro differentiation 
of ME49 strain of T. gondii. On Day 2 and 3 in control plates, Bag1 is decreased in comparison 
to day 2 and day 3 SNP treated plates. Day 2 Control and SNP were not treated with DAPI. 
Hence, images shown are without DAPI. By day 4 and 5 Bag1 expression is increased. On 
release of exogenous stress, Bag1 expression decreases. Nuclei are stained with DAPI (Blue). All 
the pictures shown were recorded under similar optical conditions, imaged with the same 
exposure time, and processed identically. 
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Figure B.2a: Day 2 (Green: Bag1, No DAPI). 
 
Figure B.2b: Day 3 (Green: Bag1 and Blue: DAPI). 
 
 
 
 
 
Figure B.2 (continued) 
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Figure B.2c: Day 3 SNP treated (Green: Bag1 and Blue: DAPI). 
 
                           
Figure B.2d: Revert day 1 and 2 SNP (Green: Bag1 and Blue: DAPI). 
 
 
 
 
 
 
Figure B.2 (continued) 
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Figure B.3: Western blot analysis of in vitro Bag 1 protein expression of ME49 strain of T. 
gondii. Bag 1 is not expressed for control day 2 and 3. Bag1 expression increases at day 2, day 3, 
day 4 and day 5 for SNP treated plates. 
 
M.W Molecular weight marker 
D2C Day 2 control flask 
D3C Day 3 Control flask 
D2T Day 2 SNP treated 
D3T Day 3 SNP treated 
D4T Day 4 SNP treated 
D5T Day 5 SNP treated 
RD1 Revert day 1 
RD2 Revert day 2 
70 
55 
130 
100 
40 
35 
25 
170 
Β-tubulin 
Βag1 
M.W     D2C      D3C        D2T        D3T     D4T        D5T         RD1         RD2 
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T. gondii. To identify these genes, RNA will be isolated at day 0, 1, 2, 3 and 4 post infection as 
well as 8 hours, 20 hours and 30 hours after the removal of SNP drug. These RNA samples will 
then be processed for RNA seq and genes that appear to be down/upregulated during the switch 
will be sorted by comparing the time points associated with tachyzoites to bradyzoite and 
bradyzoite to tachyzoites interconversion. Genes identified using this method would then be 
analyzed using gene networking software’s like GeneNet, which generates a network for the 
selected genes in order to identify the master regulatory gene(s). 
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